Reset
489 results

8-K - Allogene Therapeutics, Inc. (0001737287) (Filer)

SEC Filing (8-K) 2026-04-13
allogene therapeutics
Filed: 2026-04-13 AccNo: 0001193125-26-152866 Size: 133 KB Item 8.01: Other Events
Read article

Viatris to Report First Quarter 2026 Financial Results on May 7, 2026

PR Newswire 2026-04-13
financial results
PITTSBURGH, April 13, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced it will report first quarter 2026 financial results on Thursday, May 7, 2026. Company executives will host a webcast at 8:30 a.m. ET on the same date to discuss the results....
Read article

InMode to Report First Quarter 2026 Financial Results and Hold Conference Call on May 6, 2026, Expects Q1 Revenue Between $81.5M-$81.7M, Reiterates FY 2026 Revenue Guidance Between $365M-$375M

PR Newswire 2026-04-13
financial results
Conference call to be held on Wednesday, May 6, 2026, at 8:30 a.m. Eastern Time YOKNEAM, Israel, April 13, 2026 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, announced today that it expects to release its financial results for...
Read article

8-K - CG Oncology, Inc. (0001991792) (Filer)

SEC Filing (8-K) 2026-04-13
cg oncology
Filed: 2026-04-13 AccNo: 0001193125-26-152044 Size: 450 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 9.01: Financial Statements and Exhibits
Read article

MiniMed to announce financial results for its fourth quarter and full fiscal year 2026

PR Newswire 2026-04-13
financial results
NORTHRIDGE, Calif., April 13, 2026 /PRNewswire/ -- MiniMed (Nasdaq: MMED), a global leader in diabetes technology, today announced that it will report financial results for its fourth quarter and full fiscal year 2026 on Wednesday, June 3, 2026. A news release will be issued at...
Read article

Medtronic to announce financial results for its fourth quarter and full fiscal year 2026

PR Newswire 2026-04-13
financial results
GALWAY, Ireland, April 13, 2026 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that it will report financial results on Wednesday, June 3, 2026, for its fourth quarter and full fiscal year 2026, which ends on Friday, April 24, 2026. A...
Read article

8-K - Sana Biotechnology, Inc. (0001770121) (Filer)

SEC Filing (8-K) 2026-04-13
sana biotechnology
Filed: 2026-04-13 AccNo: 0001193125-26-152868 Size: 561 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Read article

8-K - Allogene Therapeutics, Inc. (0001737287) (Filer)

SEC Filing (8-K) 2026-04-13
allogene therapeutics
Filed: 2026-04-13 AccNo: 0001193125-26-151999 Size: 168 KB Item 8.01: Other Events
Read article

8-K - Longeveron Inc. (0001721484) (Filer)

SEC Filing (8-K) 2026-04-10
longeveron
Filed: 2026-04-10 AccNo: 0001213900-26-042565 Size: 207 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 9.01: Financial Statements and Exhibits
Read article

CENTENE CORPORATION TO HOST 2026 FIRST QUARTER FINANCIAL RESULTS EARNINGS CALL

PR Newswire 2026-04-10
financial results
ST. LOUIS, April 10, 2026 /PRNewswire/ -- Centene Corporation (NYSE: CNC), a leading healthcare enterprise committed to helping people live healthier lives, shared today that it will release its 2026 first quarter financial results at approximately 6:00 a.m. ET on Tuesday, April 28, 2026,...
Read article

INVESTOR DEADLINE: uniQure (QURE) Investors with Substantial Losses Have Opportunity to Lead the uniQure Class Action Lawsuit– Hagens Berman

uniQure 2026-04-10
financial statements
Investors who lost money in QURE after its stock plunged due to allegedly misleading financial statements are urged to contact Hagens Berman....
Read article

8-K - Intellia Therapeutics, Inc. (0001652130) (Filer)

SEC Filing (8-K) 2026-04-10
intellia therapeutics
Filed: 2026-04-10 AccNo: 0001193125-26-151300 Size: 285 KB Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Item 9.01: Financial Statements and Exhibits
Read article

8-K/A - Assertio Holdings, Inc. (0001808665) (Filer)

SEC Filing (8-K) 2026-04-09
assertio
Filed: 2026-04-09 AccNo: 0001104659-26-041569 Size: 2 MB Item 1.01: Entry into a Material Definitive Agreement Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Read article

8-K - enGene Therapeutics Inc. (0001980845) (Filer)

SEC Filing (8-K) 2026-04-09
engene
Filed: 2026-04-09 AccNo: 0001193125-26-149597 Size: 1 MB Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Read article

West to Host First-Quarter 2026 Conference Call

PR Newswire 2026-04-09
financial results
EXTON, Pa., April 9, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it will release first-quarter 2026 financial results before the market opens on Thursday, April 23,...
Read article

8-K - ImmunityBio, Inc. (0001326110) (Filer)

SEC Filing (8-K) 2026-04-09
immunitybio
Filed: 2026-04-09 AccNo: 0001326110-26-000036 Size: 217 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read article

111, Inc. Announces Fourth Quarter and Fiscal Year 2025 Financial Results

PR Newswire 2026-04-09
financial results
Continuing Transition to an Asset-Light Business Model to Improve Overall Efficiency Delivered Non-GAAP Operating Profitability in Both Q4'25 and FY'25 Generated Positive Operating Cash Flow for Both Q4'25 and FY'25 Continued Gross Profit Margin Expansion for B2B Business in Both Q4'25...
Read article

Illumina to Announce First Quarter 2026 Financial Results on Thursday, April 30, 2026

PR Newswire 2026-04-09
financial results
SAN DIEGO, April 9, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) announced today that it will issue results for the first quarter 2026 following the close of market on Thursday, April 30, 2026. On the same day, at 1:30 pm Pacific Time (4:30 pm Eastern Time) Jacob Thaysen, PhD, Chief...
Read article

BD to Announce Financial Results for its Second Quarter of Fiscal 2026

PR Newswire 2026-04-09
financial results
FRANKLIN LAKES, N.J., April 9, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that BD management will host an audio webcast at 8 a.m. ET on Thursday, May 7, 2026 to discuss the Company's financial results...
Read article

8-K - Forte Biosciences, Inc. (0001419041) (Filer)

SEC Filing (8-K) 2026-04-09
forte biosciences
Filed: 2026-04-09 AccNo: 0001193125-26-148796 Size: 469 KB Item 1.01: Entry into a Material Definitive Agreement Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Read article

Select Medical Holdings Corporation to Announce First Quarter 2026 Results on Thursday, April 30, 2026

PR Newswire 2026-04-09
financial results
MECHANICSBURG, Pa., April 9, 2026 /PRNewswire/ -- Select Medical Holdings Corporation ("Select Medical") (NYSE: SEM), will release the financial results for its first quarter ended March 31, 2026 on Thursday, April 30, 2026 after the market closes. Select Medical will host a conference...
Read article

8-K - Assertio Holdings, Inc. (0001808665) (Filer)

SEC Filing (8-K) 2026-04-09
assertio
Filed: 2026-04-09 AccNo: 0001104659-26-041236 Size: 2 MB Item 1.01: Entry into a Material Definitive Agreement Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Read article

8-K - Autolus Therapeutics plc (0001730463) (Filer)

SEC Filing (8-K) 2026-04-08
autolus therapeutics
Filed: 2026-04-08 AccNo: 0001730463-26-000043 Size: 7 MB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Read article

Envista Schedules First Quarter 2026 Earnings Call

PR Newswire 2026-04-08
financial results
BREA, Calif., April 8, 2026 /PRNewswire/ -- Envista Holdings Corporation (NYSE: NVST) ("Envista") will report financial results for its first quarter 2026 on Wednesday, May 6, 2026. Envista will discuss these results on a conference call on the same day beginning at 2:00 PM PT and lasting...
Read article

Nurix Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update

nurix therapeutics 2026-04-08
financial results accelerated approval
Enrolling Phase 2 DAYBreak CLL-201 bexobrutideg trial designed to support Accelerated Approval in relapsed/refractory chronic lymphocytic leukemia (r/r CLL) Enabling Phase 3 DAYBreak CLL-306 bexobrutideg confirmatory trial for full approval in r/r CLL Targeting 2026 IND submission for bexobrutideg
Read article

8-K - Nurix Therapeutics, Inc. (0001549595) (Filer)

SEC Filing (8-K) 2026-04-08
nurix therapeutics
Filed: 2026-04-08 AccNo: 0001549595-26-000024 Size: 238 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read article

Globe Life Inc. Announces First Quarter 2026 Earnings Release and Conference Call

PR Newswire 2026-04-08
financial results
MCKINNEY, Texas, April 8, 2026 /PRNewswire/ -- Globe Life Inc. (NYSE: GL) will announce its First Quarter 2026 financial results after the market closes on Wednesday, April 22, 2026. At that time, a copy of the Company's First Quarter 2026 earnings press release and any other financial...
Read article

8-K - REGENERON PHARMACEUTICALS, INC. (0000872589) (Filer)

SEC Filing (8-K) 2026-04-08
regeneron pharmaceuticals
Filed: 2026-04-08 AccNo: 0001104659-26-040661 Size: 193 KB Item 2.02: Results of Operations and Financial Condition
Read article

INVESTOR DEADLINE: uniQure (QURE) Investors with Substantial Losses Have Opportunity to Lead the uniQure Class Action Lawsuit– Hagens Berman

uniQure 2026-04-08
financial statements
Investors who lost money in QURE after its stock plunged due to allegedly misleading financial statements are urged to contact Hagens Berman....
Read article

10-Q - Nurix Therapeutics, Inc. (0001549595) (Filer)

SEC Filing (10-Q) 2026-04-08
nurix therapeutics
Filed: 2026-04-08 AccNo: 0001549595-26-000025 Size: 6 MB
Read article

Welltower Announces Date of First Quarter 2026 Earnings Release, Conference Call and Webcast

PR Newswire 2026-04-08
financial results
TOLEDO, Ohio, April 8, 2026 /PRNewswire/ -- Welltower® Inc. (NYSE: WELL) today announced it will release first quarter 2026 financial results after the close of trading on the New York Stock Exchange on Tuesday, April 28, 2026. The Company will host a conference call and webcast on...
Read article

8-K - Ginkgo Bioworks Holdings, Inc. (0001830214) (Filer)

SEC Filing (8-K) 2026-04-07
ginkgo bioworks
Filed: 2026-04-07 AccNo: 0001628280-26-024101 Size: 345 KB Item 2.01: Completion of Acquisition or Disposition of Assets Item 9.01: Financial Statements and Exhibits
Read article

Evolent To Release First Quarter 2026 Financial Results on Thursday, May 7, 2026

PR Newswire 2026-04-07
financial results
WASHINGTON, April 7, 2026 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company focused on achieving better health outcomes for people with complex conditions, today announced it will release its first quarter 2026 financial results on Thursday, May 7, 2026, before market open, with...
Read article

8-K - ABEONA THERAPEUTICS INC. (0000318306) (Filer)

SEC Filing (8-K) 2026-04-07
abeona therapeutics
Filed: 2026-04-07 AccNo: 0001493152-26-015451 Size: 228 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Read article

8-K - Editas Medicine, Inc. (0001650664) (Filer)

SEC Filing (8-K) 2026-04-07
editas
Filed: 2026-04-07 AccNo: 0001650664-26-000030 Size: 161 KB Item 4.01: Changes in Registrant's Certifying Accountant Item 9.01: Financial Statements and Exhibits
Read article

8-K - ImmunityBio, Inc. (0001326110) (Filer)

SEC Filing (8-K) 2026-04-06
immunitybio
Filed: 2026-04-06 AccNo: 0001193125-26-142932 Size: 169 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Read article

8-K - BIOGEN INC. (0000875045) (Filer)

SEC Filing (8-K) 2026-04-06
biogen
Filed: 2026-04-06 AccNo: 0000875045-26-000039 Size: 201 KB Item 2.02: Results of Operations and Financial Condition
Read article

QURE 1-WEEK DEADLINE ALERT: Hagens Berman Updates uniQure (QURE) Investigation Following Public FDA Rebukes and Allegations of “Distorted” Data

uniQure 2026-04-06
financial statements
Investors who lost money in QURE after its stock plunged due to allegedly misleading financial statements are urged to contact Hagens Berman....
Read article

8-K - INOVIO PHARMACEUTICALS, INC. (0001055726) (Filer)

SEC Filing (8-K) 2026-04-06
inovio pharmaceuticals
Filed: 2026-04-06 AccNo: 0001193125-26-142885 Size: 808 KB Item 1.01: Entry into a Material Definitive Agreement Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Read article

Vertex to Announce First Quarter 2026 Financial Results on May 4th

Vertex 2026-04-06
financial results
BOSTON --(BUSINESS WIRE)--Apr. 6, 2026-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first quarter 2026 financial results on Monday, May 4, 2026, after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET.
Read article

8-K - Opus Genetics, Inc. (0001228627) (Filer)

SEC Filing (8-K) 2026-04-06
opus genetics
Filed: 2026-04-07 AccNo: 0001140361-26-013394 Size: 1 MB Item 1.01: Entry into a Material Definitive Agreement Item 3.02: Unregistered Sales of Equity Securities Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Read article

8-K - AbbVie Inc. (0001551152) (Filer)

SEC Filing (8-K) 2026-04-03
abbvie
Filed: 2026-04-03 AccNo: 0001551152-26-000011 Size: 261 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read article

Avantor® to Report First Quarter 2026 Earnings on Wednesday, April 29, 2026

PR Newswire 2026-04-03
financial results
RADNOR, Pa., April 3, 2026 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that it will release its first quarter 2026 financial results before...
Read article

8-K - Instil Bio, Inc. (0001789769) (Filer)

SEC Filing (8-K) 2026-04-03
instil bio
Filed: 2026-04-03 AccNo: 0001789769-26-000024 Size: 158 KB Item 4.01: Changes in Registrant's Certifying Accountant Item 9.01: Financial Statements and Exhibits
Read article

8-K - Celldex Therapeutics, Inc. (0000744218) (Filer)

SEC Filing (8-K) 2026-04-02
celldex therapeutics
Filed: 2026-04-02 AccNo: 0001104659-26-038882 Size: 592 KB Item 1.01: Entry into a Material Definitive Agreement Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Read article

Aflac Incorporated to Release First Quarter Results and CFO Video Update on April 29, 2026 and Host Webcast on April 30, 2026

PR Newswire 2026-04-02
financial results
COLUMBUS, Ga., April 2, 2026 /PRNewswire/ -- Aflac Incorporated (NYSE: AFL) announced today that it will release first quarter 2026 financial results after the market closes on Wednesday, April 29, 2026. At that time, earnings materials, including the quarterly earnings release and...
Read article

Celyad Oncology reports full year 2025 financial results and business highlights

Celyad 2026-04-02
financial results
Mont-Saint-Guibert, Belgium; April 02, 2026, 7:00 pm CET; regulated information – Celyad Oncology (Euronext: CYAD) (the “Company”), today announces its The post Celyad Oncology reports full year 2025 financial results and business highlights appeared first on .
Read article

QURE SHAREHOLDER ALERT: Hagens Berman Updates uniQure (QURE) Investigation Following Public FDA Rebukes and Allegations of “Distorted” Data

uniQure 2026-04-02
financial statements
Investors who lost money in QURE after its stock plunged due to allegedly misleading financial statements are urged to contact Hagens Berman....
Read article

8-K - INOVIO PHARMACEUTICALS, INC. (0001055726) (Filer)

SEC Filing (8-K) 2026-04-02
inovio pharmaceuticals
Filed: 2026-04-02 AccNo: 0001193125-26-138870 Size: 136 KB Item 8.01: Other Events
Read article

8-K - Ultragenyx Pharmaceutical Inc. (0001515673) (Filer)

SEC Filing (8-K) 2026-04-02
ultragenyx
Filed: 2026-04-02 AccNo: 0001193125-26-139084 Size: 154 KB Item 8.01: Other Events
Read article

The Cigna Group's First Quarter 2026 Earnings Release Details

PR Newswire 2026-04-02
financial results
BLOOMFIELD, Conn., April 2, 2026 /PRNewswire/ -- Global health company The Cigna Group (NYSE:CI) will release its first quarter 2026 financial results on Thursday, April 30, 2026, and will host a conference call the same day. First quarter 2026 financial results will be released no later...
Read article

8-K - BioCardia, Inc. (0000925741) (Filer)

SEC Filing (8-K) 2026-04-02
biocardia
Filed: 2026-04-02 AccNo: 0001437749-26-010967 Size: 175 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Read article

8-K - Senti Biosciences, Inc. (0001854270) (Filer)

SEC Filing (8-K) 2026-04-01
senti biosciences
Filed: 2026-04-01 AccNo: 0001628280-26-022824 Size: 147 KB Item 8.01: Other Events
Read article

GenSight Biologics Confirms Definitive Full-Year 2025 Consolidated Financial Results Are in Line with Estimates

GenSight Biologics 2026-04-01
financial results
Read article

Haemonetics Sets Date for Publishing Fourth Quarter and Fiscal Year 2026 Results: May 7, 2026

PR Newswire 2026-04-01
financial results
BOSTON, April 1, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish fourth quarter fiscal year 2026 financial results at 6:00 am ET on Thursday, May 7, 2026. The Company will hold a conference call with investors and analysts to discuss...
Read article

Autolus Therapeutics plc (NASDAQ:AUTL) Q4 2025 Earnings Call Transcript

Autolus Therapeutics 2026-04-01
financial results
Operator: Good day, and thank you for standing by. Welcome to the Autolus Fourth Quarter 2025 and Full Year 2025 Financial Results Conference Call.
Read article

Adagene Reports Full Year 2025 Financial Results and Provides Corporate Update

AdaGene 2026-04-01
financial results
In 2025, muzastotug showed 29% confirmed overall response rate (ORR) among 21 patients with MSS CRC in the 20 mg/kg dose cohorts Median overall survival (OS) for the 10 mg/kg cohorts was 19.4 months, with a median follow-up of 17.8 months 4% overall discontinuation rate, no dose limiting
Read article

Labcorp to Announce First Quarter Financial Results on April 30, 2026

PR Newswire 2026-03-31
financial results
BURLINGTON, N.C., March 31, 2026 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the first quarter of 2026 before the market opens on Thursday, April 30, 2026. The company will...
Read article

Co-Diagnostics Reports Full Year 2025 Financial Results

PR Newswire 2026-03-31
financial results
Advancing Global Commercialization Strategy Through CoSara and CoMira Joint Ventures Progressing Clinical Pipeline and Regulatory Pathways for PCR Platform Strengthening Technology Leadership with AI Integration and Expanding IP Portfolio SALT LAKE CITY, March 31, 2026 /PRNewswire/ --...
Read article

AbbVie to Host First-Quarter 2026 Earnings Conference Call

Abbvie Investors 2026-03-31
financial results
NORTH CHICAGO, Ill., March 31, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its first-quarter 2026 financial results on Wednesday, April 29, 2026, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time.
Read article

VolitionRx Limited Announces Full Fiscal Year 2025 Financial Results and Business Update

PR Newswire 2026-03-31
financial results
Conference call to discuss financial and operational results scheduled for Wednesday, April 1 at 8:30 a.m. U.S. Eastern Time HENDERSON, Nev., March 31, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces...
Read article

BrainStorm Cell Therapeutics Announces Full Year 2025 Financial Results and Provides Corporate Update

PR Newswire 2026-03-31
financial results
Strategic $2.0 million post year-end financing and re-rating of BCLI shares underscore market confidence Company highlights durable long-term survival in Expanded Access Program (EAP) cohort supporting Phase 3b patient selection and inclusion criteria NEW YORK, March 31, 2026 /PRNewswire/...
Read article

Bausch Health to Announce First Quarter 2026 Results on April 29, 2026

PR Newswire 2026-03-31
financial results
LAVAL, QC, March 31, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release first quarter 2026 financial results after market close on Wednesday, April 29, 2026. Bausch Health will host a live conference call and webcast at 5:00 p.m. U.S. EDT to discuss results...
Read article

Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results

PR Newswire 2026-03-31
financial results
PALO ALTO, Calif., March 31, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the fourth quarter and full year ended December 31, 2025. "Kodiak's momentum has continued to build, highlighted by positive Phase 3...
Read article

Xtant Medical Reports Fourth Quarter and Full-Year 2025 Financial Results

PR Newswire 2026-03-31
financial results
Full year 2025 revenue totals $133.9 million, an increase of 14% year-over-year Xtant delivers positive net income, adjusted EBITDA and operating cash flow Total cash of $17.3 million as of December 31, 2025 with an additional $10.5 million received subsequent to year end related to...
Read article

QURE INVESTOR ALERT: Hagens Berman Updates uniQure (QURE) Investigation Following Public FDA Rebukes and Allegations of “Distorted” Data

uniQure 2026-03-31
financial statements
Investors who lost money in QURE after its stock plunged due to allegedly misleading financial statements are urged to contact Hagens Berman....
Read article

Perimeter Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial Results Marked by Record Revenues and Improved Operating Performance

PR Newswire 2026-03-31
financial results
Conference Call/Webcast Today at 5:00 pm ET TORONTO and DALLAS, March 31, 2026 /PRNewswire/ - Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTCQX: PYNKF) ("Perimeter" or the "Company"), a commercial-stage medical technology company, today reported preliminary unaudited financial...
Read article

BrainStorm Cell Therapeutics Announces Full Year 2025 Financial Results and Provides Corporate Update

BrainStorm Cell Therapeutics 2026-03-31
financial results
Read article

8-K - ImmunityBio, Inc. (0001326110) (Filer)

SEC Filing (8-K) 2026-03-31
immunitybio
Filed: 2026-03-31 AccNo: 0001193125-26-133363 Size: 1 MB Item 1.01: Entry into a Material Definitive Agreement Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Read article

IDenta Corp Reports 2025 Financial Results, Achieves Continued Profitability and Strengthens Balance Sheet for Global Expansion

PR Newswire 2026-03-31
financial results
HOLLYWOOD, Fla., March 31, 2026 /PRNewswire/ -- IDenta Corp. (OTCQB: IDTA), a global leader in rapid field detection and forensic identification solutions, today announced its financial results for the year ended December 31, 2025, demonstrating continued profitability, improved financial...
Read article

Keenova Announces Unaudited Fourth Quarter 2025 Financial Results

PR Newswire 2026-03-31
financial results
Robust Fourth-Quarter Performance Driven by Strength in Acthar® Gel1 and XIAFLEX®2 Financial and Operational Performance Exceeded Expectations as Company Completed Transition into Branded Therapeutics Company Hammer Toe Trial Meets Primary Safety Endpoint and Secondary, Exploratory...
Read article

Nomadar Secures $2M in 2026 Revenue, More Than Doubling 2025

PR Newswire 2026-03-31
financial results
Nomadar Reports FY2025 Results and Corporate Highlights MARSHALL, Texas, March 31, 2026 /PRNewswire/ -- Nomadar (NASDAQ: NOMA) ("Nomadar" or the "Company"), a global sports development and technology platform, today announced its financial results for the fiscal year ended December 31,...
Read article

8-K - Protara Therapeutics, Inc. (0001359931) (Filer)

SEC Filing (8-K) 2026-03-30
protara therapeutics
Filed: 2026-03-30 AccNo: 0001213900-26-035971 Size: 190 KB Item 7.01: Regulation FD Disclosure
Read article

Harbour BioMed Reports Full Year 2025 Financial Results: Sustained Global Collaboration Underpins Long-Term Growth

PR Newswire 2026-03-30
financial results
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, March 30, 2026 /PRNewswire/ -- Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other areas,...
Read article

8-K - Ultragenyx Pharmaceutical Inc. (0001515673) (Filer)

SEC Filing (8-K) 2026-03-30
ultragenyx
Filed: 2026-03-30 AccNo: 0001193125-26-130498 Size: 155 KB Item 8.01: Other Events
Read article

Autolus Therapeutics Q4 Earnings Call Highlights

Autolus Therapeutics 2026-03-27
aucatzyl financial results
Autolus Therapeutics (NASDAQ:AUTL) executives highlighted a “very good first year of launch” for AUCATZYL during the company’s fourth-quarter and full-year 2025 financial results call, pointing to $74.3 million in revenue recognized in 2025, expanded U.S. treatment-center activation, and early real-
Read article

GenSight Biologics Reports Estimated Full-Year Consolidated Financial Results for 2025

GenSight Biologics 2026-03-27
financial results
Read article

Autolus Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates

syncona 2026-03-27
financial results
Read article

Akeso Reports Full-Year 2025 Financial Results

PR Newswire 2026-03-27
financial results
HONG KONG, March 26, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced its 2025 annual results, highlighting a year of comprehensive, strategic leaps across all facets of its business. Commercial Operations Enter a New Phase of Growth In 2025, Akeso achieved...
Read article

8-K - Autolus Therapeutics plc (0001730463) (Filer)

SEC Filing (8-K) 2026-03-27
autolus therapeutics
Filed: 2026-03-27 AccNo: 0001730463-26-000032 Size: 5 MB Item 2.02: Results of Operations and Financial Condition Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Read article

Humacyte Announces Fourth Quarter and Year End 2025 Financial Results and Provides Business Update

Humacyte 2026-03-27
financial results
Total revenues from sales and research collaborations were $0.5 million for fourth quarter and $2.0 million for full year - - Purchase commitment received for a minimum of $1.475 million for a clinical evaluation and outreach program in the Kingdom of Saudi Arabia - - Submitted of a Marketing
Read article

Instil Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Instil Bio 2026-03-27
financial results
Company evaluating potential acquisitions and in-licensing opportunities to drive next phase of strategic development Cash position of $76.3 million as of December 31, 2025 expected to fund current operating plan beyond 2027 DALLAS, March 27, 2026 (GLOBE NEWSWIRE) -- Instil Bio, Inc.
Read article

8-K - MiNK Therapeutics, Inc. (0001840229) (Filer)

SEC Filing (8-K) 2026-03-27
mink therapeutics
Filed: 2026-03-27 AccNo: 0001193125-26-127931 Size: 151 KB Item 8.01: Other Events
Read article

Intensity Therapeutics Reports 2025 Year End Financial Results and Highlights, and Provides Corporate Update

PR Newswire 2026-03-27
financial results
Raised over $20 million in gross proceeds in 2025 and held $11.9 million in cash and cash equivalents as of December 31, 2025, with a cash runway into the second quarter of 2027 IT-01 Study manuscript of INT230-6 used alone in 64 refractory metastatic cancer patients published in the...
Read article

Autolus Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates

Autolus Therapeutics 2026-03-27
aucatzyl financial results
AUCATZYL ® (obecabtagene autoleucel) net product revenue of $23.3 million* for the fourth quarter of 2025 and $74.3 million* for th | Bitget crypto news!
Read article

QURE ALERT: Hagens Berman Updates uniQure (QURE) Investigation Following Public FDA Rebukes and Allegations of “Distorted” Data

uniQure 2026-03-27
financial statements
Investors who lost money in QURE after its stock plunged due to allegedly misleading financial statements are urged to contact Hagens Berman....
Read article

QURE ALERT: Hagens Berman Updates uniQure (QURE) Investigation Following Public FDA Rebukes and Allegations of “Distorted” Data

uniQure 2026-03-27
financial statements
Investors who lost money in QURE after its stock plunged due to allegedly misleading financial statements are urged to contact Hagens Berman....
Read article

8-K - Senti Biosciences, Inc. (0001854270) (Filer)

SEC Filing (8-K) 2026-03-27
senti biosciences
Filed: 2026-03-27 AccNo: 0001628280-26-021578 Size: 237 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read article

8-K - Vor Biopharma Inc. (0001817229) (Filer)

SEC Filing (8-K) 2026-03-27
vor biopharma
Filed: 2026-03-27 AccNo: 0001193125-26-127609 Size: 874 KB Item 1.01: Entry into a Material Definitive Agreement Item 3.02: Unregistered Sales of Equity Securities Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Read article

8-K - MeiraGTx Holdings plc (0001735438) (Filer)

SEC Filing (8-K) 2026-03-26
meiragtx
Filed: 2026-03-26 AccNo: 0001104659-26-034904 Size: 355 KB Item 1.01: Entry into a Material Definitive Agreement Item 2.02: Results of Operations and Financial Condition Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant Item 9.01: Financial Statements and Exhibits
Read article

Ping An Reports 2025 Performance on Positive Trends, Operating Profit[1] Up 10.3% YoY

PR Newswire 2026-03-26
financial results
Cash Dividend Increases for 14th Consecutive Year to RMB48,891 million HONG KONG and SHANGHAI, March 26, 2026 /PRNewswire/ -- Ping An Insurance (Group) Company of China, Ltd. (hereafter "Ping An" or the "Group", HKEX: 2318; SSE: 601318) today announced its financial results for the year...
Read article

8-K - Century Therapeutics, Inc. (0001850119) (Filer)

SEC Filing (8-K) 2026-03-26
century therapeutics
Filed: 2026-03-26 AccNo: 0001104659-26-035256 Size: 223 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Read article

8-K - Ocugen, Inc. (0001372299) (Filer)

SEC Filing (8-K) 2026-03-26
ocugen
Filed: 2026-03-27 AccNo: 0001628280-26-021541 Size: 5 MB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Read article

Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

Kyverna Therapeutics 2026-03-26
bla car financial results myasthenia gravis stiff person syndrome
Advancing first-to-market autoimmune CAR T opportunity in stiff person syndrome (SPS) with key launch preparation activities underway; BLA submission anticipated in 1H 2026 Progressing enrollment for FDA-aligned Phase 3 trial in generalized myasthenia gravis (gMG) Positive progressive multiple
Read article

Syncona : Autolus Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates

Autolus Therapeutics 2026-03-26
financial results
LONDON and GAITHERSBURG, Md., March 27, 2026 -- Autolus Therapeutics plc , a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell...
Read article

Precigen Reports Full Year 2025 Financial Results and Business Updates

PR Newswire 2026-03-25
papzimeos financial results
Precigen transitioned to a commercial stage company with the US approval of PAPZIMEOS™ (zopapogene imadenovec-drba), the first-and-only FDA-approved treatment for adults with RRP, in August 2025 PAPZIMEOS generated $3.4 million in net product revenue in the fourth quarter of 2025,...
Read article

8-K - PTC THERAPEUTICS, INC. (0001070081) (Filer)

SEC Filing (8-K) 2026-03-25
ptc therapeutics
Filed: 2026-03-25 AccNo: 0001104659-26-034207 Size: 183 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Read article

QURE ALERT: Hagens Berman Updates uniQure (QURE) Investigation Following Public FDA Rebukes and Allegations of “Distorted” Data

uniQure 2026-03-25
financial statements
Investors who lost money in QURE after its stock plunged due to allegedly misleading financial statements are urged to contact Hagens Berman....
Read article

Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2025 Financial Results

PR Newswire 2026-03-25
financial results
LOS ANGELES, March 25, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of...
Read article

8-K - Nkarta, Inc. (0001787400) (Filer)

SEC Filing (8-K) 2026-03-25
nkarta
Filed: 2026-03-26 AccNo: 0001787400-26-000008 Size: 166 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Read article

Waterdrop Inc. Announces Fourth Quarter and Fiscal Year 2025 Unaudited Financial Results and Declares a Cash Dividend

PR Newswire 2026-03-25
financial results
BEIJING, March 25, 2026 /PRNewswire/ -- Waterdrop Inc. ("Waterdrop", the "Company" or "we") (NYSE: WDH), a leading technology platform dedicated to insurance and healthcare service with a positive social impact, today announced its unaudited financial results for the three and twelve...
Read article

8-K - Immix Biopharma, Inc. (0001873835) (Filer)

SEC Filing (8-K) 2026-03-25
immix biopharma
Filed: 2026-03-25 AccNo: 0001493152-26-012721 Size: 280 KB Item 1.01: Entry into a Material Definitive Agreement Item 9.01: Financial Statements and Exhibits
Read article

Nkarta Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights

nkarta 2026-03-25
nkx019 financial results
Dose escalation for NKX019 advanced to 4 billion cells per dose on days 0, 3 and 7 for a total of 12 billion cells per cycle Initial clinical data from Ntrust-1 and Ntrust-2 targeted for presentation at a medical conference in 2026 Cash balance of $295.1 million on December 31, 2025, including
Read article

Health In Tech Announces Fourth Quarter and Full Year 2025 Financial Results

PR Newswire 2026-03-25
financial results
Full year 2025 Revenues of $33.3 million, up 71% YoY Full year 2025 Adjusted EBITDA of $4.1 million, up 81% YoY STUART, Fla., March 25, 2026 /PRNewswire/ -- Health In Tech, Inc. (Nasdaq: HIT) ("Health In Tech" or "Company"), an AI-enabled InsurTech platform company, today announced its...
Read article

CytoSorbents Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

PR Newswire 2026-03-25
financial results
2025 revenue of $37.1 million, up 4% year-over-year, and 71% Full-year gross margins Enhanced Balance Sheet Flexibility with an Additional $2.5 million Proceeds from Amended Credit Facility in November Implemented Strategic Workforce and Cost Reduction Program in Q4 to Accelerate Timing...
Read article

8-K - PRECIGEN, INC. (0001356090) (Filer)

SEC Filing (8-K) 2026-03-25
precigen
Filed: 2026-03-25 AccNo: 0000950103-26-004648 Size: 275 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read article

8-K - Neurogene Inc. (0001404644) (Filer)

SEC Filing (8-K) 2026-03-24
neurogene
Filed: 2026-03-24 AccNo: 0001404644-26-000012 Size: 8 MB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read article

Cardinal Health to Announce Third-Quarter Results for Fiscal Year 2026 on April 30

PR Newswire 2026-03-24
financial results
DUBLIN, Ohio, March 24, 2026 /PRNewswire/ -- Cardinal Health (NYSE: CAH) plans to release third-quarter financial results for its fiscal year 2026 on April 30 as previously indicated, prior to the opening of trading on the New York Stock Exchange. The company will webcast a discussion of...
Read article

LENZ Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights

LENZ Therapeutics 2026-03-24
financial results
Read article

Neurogene Reports Full Year 2025 Financial Results and Highlights Recent Updates

neurogene 2026-03-24
financial results
100% of participants enrolled in Embolden™ registrational trial and >50% of participants dosed; on track to complete dosing in second quarter of 2026 NGN-401 has been generally well-tolerated in Phase 1/2 trial and Embolden, with no cases of HLH at the 1E15 vg dose; additional interim Phase 1/2
Read article

8-K - Ocugen, Inc. (0001372299) (Filer)

SEC Filing (8-K) 2026-03-24
ocugen
Filed: 2026-03-24 AccNo: 0001104659-26-033724 Size: 10 MB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Read article

8-K - BioCardia, Inc. (0000925741) (Filer)

SEC Filing (8-K) 2026-03-24
biocardia
Filed: 2026-03-24 AccNo: 0001437749-26-009609 Size: 256 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read article

Cabaletta Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

cabaletta bio 2026-03-23
financial results
Read article

8-K - Cabaletta Bio, Inc. (0001759138) (Filer)

SEC Filing (8-K) 2026-03-23
cabaletta bio
Filed: 2026-03-23 AccNo: 0001759138-26-000010 Size: 26 MB Item 2.02: Results of Operations and Financial Condition Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Read article

8-K - Imunon, Inc. (0000749647) (Filer)

SEC Filing (8-K) 2026-03-23
imunon
Filed: 2026-03-23 AccNo: 0001493152-26-012164 Size: 306 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Read article

BioLineRx Reports 2025 Financial Results and Provides Corporate Update

PR Newswire 2026-03-23
financial results
On track to initiate Phase 1/2a clinical trial of GLIX1 for treatment of glioblastoma (GBM) by end of this month - - GLIX1 is positioned to potentially address unmet needs for novel and more effective cancer treatments by targeting DNA damage response mechanisms - - Management to host...
Read article

Humacyte To Announce 2025 Fourth Quarter and Year End Financial Results and Provide Business Update on March 27, 2026

Humacyte 2026-03-23
financial results
DURHAM, N.C., March 23, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that the Company will release its financial results for the quarter
Read article

Perimeter Schedules Fourth Quarter and Full Year 2025 Financial Results Conference Call for March 31st; Provides Corporate Update

PR Newswire 2026-03-23
financial results
TORONTO and DALLAS, March 23, 2026 /PRNewswire/ - Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTCQX: PYNKF) ("Perimeter" or the "Company"), a commercial-stage medical technology company, announced it will report its fourth quarter and full year 2025 financial and operating results...
Read article

Q4 Financial Results Overview: BioMarin Pharmaceutical (NASDAQ:BMRN) Compared to Other Therapeutics Stocks

BioMarin Pharmaceutical 2026-03-20
financial results
Therapeutics Sector Q4 Overview Quarterly earnings reports can provide valuable insight into where a company is headed in the near future. With the fourth q | Bitget crypto news!
Read article

8-K - ABEONA THERAPEUTICS INC. (0000318306) (Filer)

SEC Filing (8-K) 2026-03-20
abeona therapeutics
Filed: 2026-03-20 AccNo: 0001493152-26-011863 Size: 211 KB Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Item 9.01: Financial Statements and Exhibits
Read article

8-K - TG THERAPEUTICS, INC. (0001001316) (Filer)

SEC Filing (8-K) 2026-03-20
tg therapeutics
Filed: 2026-03-20 AccNo: 0001437749-26-009253 Size: 169 KB Item 1.01: Entry into a Material Definitive Agreement Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant Item 9.01: Financial Statements and Exhibits
Read article

8-K - Ocugen, Inc. (0001372299) (Filer)

SEC Filing (8-K) 2026-03-20
ocugen
Filed: 2026-03-20 AccNo: 0001104659-26-032442 Size: 186 KB Item 8.01: Other Events
Read article

8-K - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Filer)

SEC Filing (8-K) 2026-03-20
iovance biotherapeutics
Filed: 2026-03-20 AccNo: 0001104659-26-032774 Size: 189 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Read article

8-K - REGENXBIO Inc. (0001590877) (Filer)

SEC Filing (8-K) 2026-03-20
regenxbio
Filed: 2026-03-20 AccNo: 0001193125-26-117913 Size: 147 KB Item 1.01: Entry into a Material Definitive Agreement
Read article

8-K - Humacyte, Inc. (0001818382) (Filer)

SEC Filing (8-K) 2026-03-19
humacyte
Filed: 2026-03-19 AccNo: 0001104659-26-032116 Size: 702 KB Item 1.01: Entry into a Material Definitive Agreement Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Read article

Cellectis Reports Full Year 2025 Financial Results and Provides a Business Update

cellectis 2026-03-19
bla car cd19 cd20 cd22 cellectis allogeneic astrazeneca financial results
Pivotal Phase 2 with lasme-cel in r/r B-ALL (BALLI-01 trial) ongoing Phase 1: 83% ORR at RP2D and 100% ORR in the target Phase 2 population In target Phase 2 population: 100% of patients became eligible to transplant Pivotal Phase 2 first interim analysis expected in Q4 2026 BLA submission anticipated in 2028 Phase 1 with eti-cel in r/r NHL (NATHALI-01 trial) ongoing Best-in-class dual allogeneic CAR-T cell product targeting CD20 & CD22 At current dose level, 88% ORR; 63% CR rate after 2+ prior lines of therapy 93% of subjects had prior CD19 CAR-T Low-dose IL-2 cohort to be included in; Full Phase 1 dataset expected in Q4 2026 Partnerships Servier (through Allogene): Pivotal randomized Phase 2 ALPHA3 trial with cema-cel in 1L consolidation in LBCL: interim futility analysis evaluating MRD clearance and early safety results planned for April 2026 AstraZeneca: Activities progressing under the Joint Research and Collaboration Agreement Cash, cash equivalents and fixed-term deposits of $211 million as of December 31, 2025 [1] provides runway into H2 2027 Conference call scheduled on March 20, 2026 at 8:00 am ET / 1:00 pm CET New Yo
Read article

8-K - MiNK Therapeutics, Inc. (0001840229) (Filer)

SEC Filing (8-K) 2026-03-19
mink therapeutics
Filed: 2026-03-19 AccNo: 0001193125-26-116219 Size: 158 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Read article

Brii Biosciences Provides Corporate Updates and Reports Full Year 2025 Financial Results

PR Newswire 2026-03-19
financial results
Advancing HBV Functional Cure Toward Key Phase 2b Data Readouts Increasing Discovery Efforts to Drive Long-term Value Creation Strong Cash Position Supporting Strategic Priorities Upcoming Conference Calls: English Session: March 20 at 8:30 p.m. HKT / 8:30 a.m. ET Chinese Session: March...
Read article

Inhibrx Reports Fourth Quarter and Fiscal Year 2025 Financial Results

PR Newswire 2026-03-19
financial results
SAN DIEGO, March 19, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the fourth quarter and fiscal year 2025. Following the completion of the sale of INBRX-101 (the "101 Transaction") by Inhibrx, Inc. (the...
Read article

SERA PROGNOSTICS REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS

PR Newswire 2026-03-18
financial results
SALT LAKE CITY, March 18, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the fourth...
Read article

Abeona Therapeutics® Reports Full Year 2025 Financial Results and Corporate Updates

Abeona Therapeutics 2026-03-17
financial results
Read article

LENZ Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights on March 24, 2026

LENZ Therapeutics 2026-03-17
financial results
Read article

QURE ALERT: FDA Reportedly Accuses uniQure of Pushing “Distorted” and “Manipulated” Data For “Failed” AMT-130 Drug Amid Pending Securities Class Action

uniQure 2026-03-17
amt-130 financial statements
Investors who lost money in QURE after its stock plunged due to allegedly misleading financial statements are urged to contact Hagens Berman....
Read article

Atara Biotherapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Operational Progress

Atara Biotherapeutics 2026-03-16
financial results
Read article

Keenova Therapeutics to Report Fourth-Quarter 2025 Financial Results on March 31, 2026

PR Newswire 2026-03-16
financial results
DUBLIN, March 16, 2026 /PRNewswire/ -- Keenova Therapeutics plc, a leading global developer and manufacturer of branded therapeutics, announced today that it will report its fourth-quarter 2025 financial results on Tuesday, March 31, 2026, before market open. The Company will host a...
Read article

Autolus Therapeutics to Announce Q4 and Full Year 2025 Financial Results on March 27, 2026

Autolus Therapeutics 2026-03-16
cell therapies financial results
Autolus Therapeutics will announce Q4 2025 financial results on March 27, 2026, followed by a conference call.Quiver AI SummaryAutolus Therapeutics plc, a biopharmaceutical company focused on next-generation programmed T cell therapies, announced it will release its fourth quarter and full year 2025 financial results on March 27, 2026, before U.S. market opening. A conference call and webcast hosted by management will follow at 8:30 am EDT to dis
Read article

Autolus Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 27, 2026

Autolus Therapeutics 2026-03-16
cell therapies financial results
LONDON and GAITHERSBURG, Md., March 16, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, today announced that the Company will release its fourth quarter and full year 2025 financial results and operational highlights before open of U.S. markets on Friday, March 27, 2026.
Read article

8-K - BIOMARIN PHARMACEUTICAL INC (0001048477) (Filer)

SEC Filing (8-K) 2026-03-16
biomarin pharmaceutical
Filed: 2026-03-16 AccNo: 0001193125-26-107314 Size: 137 KB Item 8.01: Other Events
Read article

Cypherpunk Reports Full Year 2025 Financial Results

PR Newswire 2026-03-16
financial results
CAMBRIDGE, Mass., March 16, 2026 /PRNewswire/ -- Cypherpunk Technologies Inc., (Nasdaq: CYPH) ("Cypherpunk"), today reported financial results for the year ended December 31, 2025. "2025 was a transformational year. Following a $58.88 million private placement led by Winklevoss Capital,...
Read article

Bioretec Ltd's Financial Statements and Annual Report 2025 published

PR Newswire 2026-03-13
financial statements
Bioretec Ltd | Company announcement | 13 March 2026 at 5:15 p.m. TAMPERE, Finland, March 13, 2026 /PRNewswire/ -- Bioretec Ltd has today published its 2025 Financial Statements and Annual Report. The publications are attached to this release and also available in Finnish and English on...
Read article

Adicet Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress

Adicet Bio 2026-03-13
lupus financial results
Strong enrollment momentum in Phase 1 autoimmune program evaluating prulacabtagene leucel (prula-cel, formerly ADI-001); clinical update expected in 1H/2026 with an additional update in 2H/2026 Achieved regulatory alignment with the FDA enabling outpatient dosing of prula-cel for lupus nephritis
Read article

Insilico Medicine to Announce 2025 Financial Results on March 30, 2026

PR Newswire 2026-03-13
financial results
CAMBRIDGE, Mass., March 13, 2026 /PRNewswire/ -- Insilico Medicine (HKEX: 3696.HK, "Insilico" or the "Company"), a clinical-stage biotechnology company powered by generative artificial intelligence for drug discovery and development, today announced that it will report its financial...
Read article

QURE ALERT: FDA Reportedly Accuses uniQure of Pushing “Distorted” and “Manipulated” Data For “Failed” AMT-130 Drug Amid Pending Securities Class Action

uniQure 2026-03-13
amt-130 financial statements
Investors who lost money in QURE after its stock plunged due to allegedly misleading financial statements are urged to contact Hagens Berman....
Read article

Bioretec Ltd's Financial Statements and Annual Report 2025 published

PR Newswire 2026-03-13
financial statements
Bioretec Ltd | Company announcement | 13 March 2026 at 5:15 p.m. TAMPERE, Finland, March 13, 2026 /PRNewswire/ -- Bioretec Ltd has today published its 2025 Financial Statements and Annual Report. The publications are attached to this release and also available in Finnish and English on...
Read article

INOVIO Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

Inovio Pharmaceuticals 2026-03-12
financial results
Read article

Precision BioSciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Update

precision biosciences 2026-03-12
financial results
PBGENE-HBV Phase 1 data featured Late Breaker presentation at AASLD, The Liver Meeting, showing safety, tolerability and cumulative, dose-dependent antiviral activity - - Strong Phase 1 ELIMINATE-B trial execution for PBGENE-HBV with 13 patients now dosed across first 5 cohorts; Data updates
Read article

Capricor Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Capricor Therapeutics 2026-03-12
financial results
Read article

Lyell Immunopharma Reports Q4 and Full Year 2025 Business and Financial Results

lyell immunopharma 2026-03-12
car b-cell lymphoma financial results large b-cell lymphoma
Patient dosing has commenced in first-of-its-kind Phase 3 head-to-head CAR T-cell 2L randomized controlled clinical trial (PiNACLE-H2H) in patients with large B-cell lymphoma, and the 3L+ pivotal trial (PiNACLE) evaluating ronde-cel is ongoing Phase 1 trial is ongoing for LYL273, an enhanced
Read article

Cellectis to Report Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026

cellectis 2026-03-12
gene therapies financial results
New York, NY – March 12, 2026 - Cellectis (the “Company”) (Euronext Growth: ALCLS, NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the fourth quarter and full year 2025 ending December 31, 2025 on Thursday, March 19, 2026 after the close of the US market. The publication will be followed by an investor conference call and webcast on Friday, March 20, 2026, at 8:00 AM ET / 1:00 PM CET. The call will include the Company’s fourth quarter and full year 2025 results and an update on business activities. Details for the call are as follows: Dial in information: Domestic: +1-800-579-2543 International: +1-785-424-1789 Conference ID: CLLSFY Webcast Link: https://viavid.webcasts.com/starthere.jsp?ei=1747993&tp_key=8aa72cea7f
Read article

8-K - Ultragenyx Pharmaceutical Inc. (0001515673) (Filer)

SEC Filing (8-K) 2026-03-12
ultragenyx
Filed: 2026-03-12 AccNo: 0001193125-26-103167 Size: 162 KB Item 8.01: Other Events
Read article

INOVIO Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

PR Newswire 2026-03-12
bla pdufa ino-3107 financial results accelerated approval
Biologics License Application (BLA) for INO-3107 accepted for review under the Accelerated Approval Program as a potential treatment for adults with Recurrent Respiratory Papillomatosis (RRP) by the U.S. Food and Drug Administration (FDA); target Prescription Drug User Fee Act (PDUFA)...
Read article

IN8bio Reports Fourth Quarter and Full-Year 2025 Financial Results - Highlights Durable Survival Improvements in Glioblastoma, Advancing Pipeline and Strengthened Financial Position for 2026

In8Bio 2026-03-12
financial results
Presented updated glioblastoma (“GBM”) data demonstrating durable survival and a favorable safety profile across Phase 1 and Phase 2 programs, with repeat dosing of DeltEx™ Drug-Resistant Immunotherapy γδ T cells (“DRI”) nearly doubling median progression-free survival (“mPFS”) to 13.0 months
Read article

ProQR Announces Year End 2025 Operating and Financial Results

proqr therapeutics 2026-03-12
rett syndrome financial results
Advancing AX-0810 through ongoing Phase 1 dosing, with target engagement data expected 1H 2026 Selected Development Candidates AX-2402 for Rett syndrome (MECP2, R270X) and AX-2911 for MASH (PNPLA3) Ended 2025 with € 92.4 million cash and cash equivalents and achieved $4.5 million in Eli Lilly collaboration milestones in 2025, supporting runway into mid-2027 LEIDEN, Netherlands & CAMBRIDGE, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today reported its financial and operating results for the year ended December 31, 2025, and provided a business update.
Read article

Allogene Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update

Allogene 2026-03-12
b-cell lymphoma financial results large b-cell lymphoma
Pivotal, Randomized Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First Line (1L) Consolidation in Large B-Cell Lymphoma (LBCL) Positions Company at the Forefront of MRD-Guided 1L Consolidation Treatment in Both Academic and Community Cancer Centers, and Advances a Broader
Read article

Nektar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

PR Newswire 2026-03-12
financial results
SAN FRANCISCO, March 12, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the fourth quarter ended December 31, 2025. Cash and investments in marketable securities on December 31, 2025 were $245.8 million as compared to $269.1 million on...
Read article

8-K - Atara Biotherapeutics, Inc. (0001604464) (Filer)

SEC Filing (8-K) 2026-03-12
atara biotherapeutics
Filed: 2026-03-12 AccNo: 0001193125-26-103127 Size: 165 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Read article

Precigen to Announce Full Year 2025 Financial Results and Provide Business Updates on March 25

PR Newswire 2026-03-11
financial results
GERMANTOWN, Md., March 11, 2026 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today announced the Company will release full year 2025 financial...
Read article

Protalix BioTherapeutics to Announce Fiscal Year 2025 Financial Results and Business Update on March 18, 2026

PR Newswire 2026-03-11
financial results
Company to host conference call and webcast at 8:00 a.m. EDT CARMIEL, Israel, March 11, 2026 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production and commercialization of innovative therapeutics...
Read article

8-K - CAPRICOR THERAPEUTICS, INC. (0001133869) (Filer)

SEC Filing (8-K) 2026-03-10
capricor therapeutics
Filed: 2026-03-10 AccNo: 0001104659-26-025657 Size: 179 KB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Read article

Everest Medicines to Announce 2025 Full-Year Financial Results on March 26, 2026

PR Newswire 2026-03-10
financial results
SHANGHAI, March 10, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that it will report its...
Read article

Q32 Bio Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update

PR Newswire 2026-03-10
financial results
Completed enrollment in Part B of SIGNAL-AA Phase 2a clinical trial and increased trial size to 33 patients based on patient demand; 36-week topline data readout expected in mid-2026 -- -- Completed $10.5 million registered direct offering (RDO) -- -- Completed asset sale of Phase 2...
Read article

The Bull Case For Krystal Biotech (KRYS) Could Change Following Q4 Beat And CEO Stock Sales

Krystal Biotech 2026-03-10
financial results
In recent weeks, Krystal Biotech reported financial results for the fourth quarter of 2025 that exceeded analyst expectations for both earnings and revenue, while President and CEO Krishnan Krish S executed US$6.58 million of pre-planned stock sales under a Rule 10b5-1 trading plan. This combination of financial outperformance and insider selling offers fresh insight into how management is monetizing equity while the core business appears to be executing ahead of external forecasts. Next,...
Read article

8-K - ROCKET PHARMACEUTICALS, INC. (0001281895) (Filer)

SEC Filing (8-K) 2026-03-10
rocket pharmaceuticals
Filed: 2026-03-10 AccNo: 0001140361-26-008853 Size: 636 KB Item 1.01: Entry into a Material Definitive Agreement Item 1.02: Termination of a Material Definitive Agreement Item 9.01: Financial Statements and Exhibits
Read article

Protara Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update

protara therapeutics 2026-03-10
bladder cancer financial results
Reported interim data from ADVANCED-2 trial in non-muscle invasive bladder cancer (NMIBC); TARA-002 demonstrated 68% complete response rate at six months in BCG-Unresponsive patients Company expects to complete enrollment of the BCG-Unresponsive registrational cohort of the ADVANCED-2 trial in 2H
Read article

Opus Genetics Announces Financial Results for Full Year 2025 and Provides Corporate Update

opus genetics 2026-03-10
financial results
Read article

enGene Reports First Quarter 2026 Financial Results and Provides Business Update

enGene Google 2026-03-09
financial results
Read article

enGene Reports First Quarter 2026 Financial Results and Provides Business Update

enGene Google 2026-03-09
financial results
BOSTON & MONTREAL--(BUSINESS WIRE)--Mar 9, 2026--
Read article

enGene Reports Q1 2026 Results, Advances Detalimogene for Bladder Cancer with Strong Cash Position and FDA Milestones 12

enGene Google 2026-03-09
bla bladder cancer financial results
enGene Holdings Inc. Reports First Quarter 2026 Financial Results and Provides Major Business Update Key Highlights LEGEND pivotal cohort update planned for a spring 2026 medical conference 12-month complete response data from LEGEND pivotal cohort expected in 2H 2026 Biologics License Application (BLA) submission for detalimogene planned for 2H 2026 Cash and marketable securities of...
Read article

enGene Reports First Quarter 2026 Financial Results and Provides Business Update

enGene Google 2026-03-09
bla financial results
LEGEND pivotal cohort update planned for a spring 2026 medical conference12-month complete response data from LEGEND pivotal cohort expected in 2H 2026Biologics License Application (BLA) submission for detalimogene planned for 2H 2026Cash and marketable securities of $312.5 million expected to pr...
Read article

10-Q - enGene Holdings Inc. (0001980845) (Filer)

SEC Filing (10-Q) 2026-03-09
engene
Filed: 2026-03-09 AccNo: 0001193125-26-097541 Size: 10 MB
Read article

Capricor Therapeutics to Present Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Update on March 12

Capricor Therapeutics 2026-03-09
financial results
Read article

enGene Reports First Quarter 2026 Financial Results and Provides Business Update

enGene Google 2026-03-09
financial results
enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced its financial results ...
Read article

QURE INVESTOR ALERT: uniQure Faces Securities Class Action Over AMT-130 Clinical Trial Design

uniQure 2026-03-09
amt-130 financial statements
Investors who lost money in QURE after its stock plunged due to allegedly misleading financial statements are urged to contact Hagens Berman....
Read article

8-K - Longeveron Inc. (0001721484) (Filer)

SEC Filing (8-K) 2026-03-06
longeveron
Filed: 2026-03-09 AccNo: 0001213900-26-024839 Size: 193 KB Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Read article

INOVIO to Report Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026

Inovio Pharmaceuticals 2026-03-05
financial results
Read article

Caribou Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

caribou biosciences 2026-03-05
crispr financial results
BERKELEY, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today reported financial results for fourth quarter and full year 2025 and provided an overview of recent corporate highlights.
Read article

Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

lineage cell therapeutics 2026-03-05
cell therapy financial results
Positive RG6501 (OpRegen ® Cell Therapy) Phase 1/2a Clinical Study 36 Month Results Featured at Clinical Trials at the Summit 2025 Achieved First Milestone Under Worldwide Collaboration with Genentech Based on RG6501 (OpRegen Cell Therapy) Program Manufacturing and Clinical Advancements
Read article

REGENXBIO Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

REGENXBIO 2026-03-05
rgx-202 gene therapy financial results duchenne muscular dystrophy
Late-stage gene therapy pipeline for rare and retinal diseases advancing toward key catalysts RGX-202 for Duchenne muscular dystrophy: New Phase I/II data at MDA, topline pivotal results expected early Q2 2026 Robust patient enrollment continues in confirmatory trial Surabgene lomparvovec
Read article

8-K - REGENXBIO Inc. (0001590877) (Filer)

SEC Filing (8-K) 2026-03-05
regenxbio
Filed: 2026-03-05 AccNo: 0001193125-26-092566 Size: 552 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read article

Immatics Announces Full Year 2025 Financial Results and Business Update

Immatics Biotechnologies 2026-03-05
melanoma cell therapy financial results
Anzu-cel (anzutresgene autoleucel, IMA203) PRAME Cell Therapy: Global, randomized, controlled Phase 3 trial, SUPRAME, in previously treated advanced melanoma ongoing; anzu-cel received Orphan Drug Designation from the FDA for the treatment of both cutaneous and uveal melanoma SUPRAME timelines
Read article

8-K - Ocugen, Inc. (0001372299) (Filer)

SEC Filing (8-K) 2026-03-04
ocugen
Filed: 2026-03-04 AccNo: 0001104659-26-023288 Size: 14 MB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read article

Cryoport Reports Fourth Quarter and Full-Year 2025 Financial Results

Cryoport Inc 2026-03-03
financial results
Read article

Passage Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Recent Business Highlights

passage bio 2026-03-03
financial results
Read article

Abeona Therapeutics® Announces Date of Fourth Quarter / Full Year 2025 Financial Results and Participation in Upcoming 2026 Leerink Global Healthcare Conference

Abeona Therapeutics 2026-03-03
financial results
Read article

8-K - Atara Biotherapeutics, Inc. (0001604464) (Filer)

SEC Filing (8-K) 2026-03-03
atara biotherapeutics
Filed: 2026-03-03 AccNo: 0001193125-26-086793 Size: 144 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Read article

ImmunityBio to Provide a Business Update and Review Financial Results for FY 2025

Immunity Bio 2026-03-03
financial results
The post ImmunityBio to Provide a Business Update and Review Financial Results for FY 2025 appeared first on ImmunityBio .
Read article

Rigel Provides Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

PR Newswire 2026-03-03
financial results
Fourth quarter 2025 total revenues of approximately $69.8 million, including record net product sales of $65.4 million and contract revenues of $4.4 million 2025 total revenues of approximately $294.3 million, including net product sales of $232.0 million and contract revenues of $62.3...
Read article

Prime Medicine Reports Full Year 2025 Financial Results and Provides Business Updates

prime medicine 2026-03-03
bla wilson disease financial results
On track to file IND and/or CTA for Wilson Disease and AATD programs in 1H 2026 and mid-2026, respectively; initial clinical data for both expected in 2027 -- -- Ongoing engagement with FDA for PM359 in CGD; plan to submit BLA following final alignment -- -- Prime Medicine reported cash, cash
Read article

Allogene Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update

Allogene 2026-03-02
car allogeneic financial results
Conference Call and Webcast Scheduled for March 12, 2026 at 2:00 p.m. PT / 5:00 p.m. ET SOUTH SAN FRANCISCO, Calif., March 02, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T)
Read article

8-K - Intellia Therapeutics, Inc. (0001652130) (Filer)

SEC Filing (8-K) 2026-03-02
intellia therapeutics
Filed: 2026-03-02 AccNo: 0001193125-26-084309 Size: 234 KB Item 1.01: Entry into a Material Definitive Agreement Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Read article

uniQure Announces 2025 Financial Results and Provides Recent Company Updates

uniQure 2026-03-02
amt-130 financial results
Held Type A meeting with FDA to discuss AMT-130 for Huntington’s disease; Company evaluating Phase III development considerations and plans to request...
Read article

CG Oncology Reports 2025 Year End Financial Results and Provides Business Updates

CG Oncology 2026-03-02
financial results
IRVINE - CG Oncology, Inc. reported financial results for the fourth quarter and year ended December 31, 2025, and provided business updates. 'In the coming months, we look forward to sharing topline...
Read article

ImmunityBio to Provide a Business Update and Review Financial Results for FY 2025 on Tuesday, March 3, 2026

Immunity Bio 2026-02-27
financial results
The post ImmunityBio to Provide a Business Update and Review Financial Results for FY 2025 on Tuesday, March 3, 2026 appeared first on ImmunityBio .
Read article

8-K - Inmune Bio, Inc. (0001711754) (Filer)

SEC Filing (8-K) 2026-02-27
inmune bio
Filed: 2026-02-27 AccNo: 0001213900-26-021120 Size: 18 MB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Read article

8-K - CG Oncology, Inc. (0001991792) (Filer)

SEC Filing (8-K) 2026-02-27
cg oncology
Filed: 2026-02-27 AccNo: 0001193125-26-079452 Size: 348 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read article

CG Oncology Reports 2025 Year End Financial Results and Provides Business Updates

CG Oncology 2026-02-27
financial results
PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC expected first half 2026CORE-008 Cohort CX Phase 2 first results of combination cretostimogene with gemcitabine in high-risk (HR) NMIBC expected first half 2026Well-positioned to deliver on key milestones with approximately $903.0 million cash, cash equivalents and marketable securities sufficient to fund operations into the first half of 2029 IRVINE, Calif., Feb. 27, 2026 (GLOB
Read article

CG Oncology Reports Strong Cash Position and Upcoming Milestones for Cretostimogene Development in NMIBC Trials

CG Oncology 2026-02-27
bladder cancer financial results
CG Oncology reported financial results and upcoming data releases for cretostimogene, targeting NMIBC treatments with significant cash reserves.Quiver AI SummaryCG Oncology, Inc. announced its financial results for the fourth quarter and year ended December 31, 2025, highlighting key advancements in their clinical trials for cretostimogene, an investigational immunotherapy for non-muscle invasive bladder cancer (NMIBC). Topline data from the PIVO
Read article

Azitra, Inc. Announces Full Year 2025 Results and Provides Business Updates

PR Newswire 2026-02-27
financial results
BRANFORD, Conn., Feb. 27, 2026 /PRNewswire/ -- Azitra, Inc. ("Azitra") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the full year ended December 31, 2025, and...
Read article

Corporate Presentation and Half Year Financial Results

Mesoblast 2026-02-26
financial results
Read article

Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Progress

Rocket Pharmaceuticals 2026-02-26
pdufa kresladi financial results
Pivotal Phase 2 trial of RP-A501 for Danon disease to resume in 1H 2026 KRESLADI ™ for severe LAD-I on track for March 28, 2026 PDUFA date Dosing of first patient in Phase 1 study of RP-A701 for BAG3-related dilated cardiomyopathy anticipated in mid-2026 Cash, cash equivalents and investments of
Read article

Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 5, 2026

lineage cell therapeutics 2026-02-26
allogeneic cell therapies financial results
CARLSBAD, Calif. --(BUSINESS WIRE)--Feb. 26, 2026-- Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic, or “off the shelf”, cell therapies for serious medical conditions, today announced that it will report its fourth quarter
Read article

Fate Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates

Fate Therapeutics 2026-02-26
car cell therapy financial results
Outpatient treatment enabled under FT819-102 autoimmune basket protocol with patients now treated with FT819 off-the-shelf CAR T-cell therapy as same-day hospital discharge Four systemic sclerosis patients and the first idiopathic inflammatory myopathy patient treated with FT819; First systemic
Read article

Intellia Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates

Intellia Therapeutics Inc. 2026-02-26
bla financial results
HAELO Phase 3 clinical data for lonvo-z in HAE expected by mid-2026; BLA submission in second half of 2026; anticipated U.S. launch in first half of 2027 Process underway to reactivate global sites for MAGNITUDE-2 Phase 3 clinical trial of nex-z in ATTRv-PN; enrollment completion expected in second
Read article

Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Developments

Sarepta Therapeutics 2026-02-25
elevidys financial results
Net product revenues for the full year 2025 totaled $1,864.3 million, consisting of $965.6 million of PMO net product revenue and $898.7 million of ELEVIDYS net product revenue Net product revenues for the fourth quarter 2025 totaled $369.6 million, consisting of $259.2 million of PMO net product
Read article

MIMEDX Announces Record Fourth Quarter and Full Year 2025 Operating and Financial Results

mimedx 2026-02-25
financial results
Net Sales Grew 27% Year-Over-Year for the Fourth Quarter and 20% for the Full Year Fourth Quarter GAAP Net Income and Earnings Per Share were $15 million and $0.10, Respectively Fourth Quarter Adjusted EBITDA 1 was $29 Million, or 25% of Net Sales Company Estimates 2026 Net Sales in a Range of
Read article

Celldex Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate UpdateDownload PDF

Celldex Therapeutics 2026-02-25
bla financial results
Enrollment completed in both Phase 3 chronic spontaneous urticaria global registration studies (EMBARQ-CSU 1 and 2) six months ahead of guidance; Topline data expected in Q4 26; BLA submission planned for 2027 Phase 3 cold urticaria and symptomatic dermographism study (EMBARQ-ColdU and -SD) Download PDF
Read article

REGENXBIO to Host Conference Call on March 5 to Discuss Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

REGENXBIO 2026-02-25
financial results
ROCKVILLE, Md., Feb. 25, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Thursday, March 5, at 8:00 a.m. ET to discuss its financial results for the fourth quarter and full year ended December 31, 2025, and operational highlights.
Read article

Penumbra, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results

PR Newswire 2026-02-25
financial results
ALAMEDA, Calif., Feb. 25, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the fourth quarter and full year ended December 31, 2025. Financial Highlights: Revenue of $385.4 million for the fourth quarter of...
Read article

Axogen, Inc. Reports Fourth Quarter and Full-Year 2025 Financial Results

axogen 2026-02-24
financial results
Read article

Axogen, Inc. Reports Fourth Quarter and Full-Year 2025 Financial Results

axogen 2026-02-24
financial results
Read article

8-K - Kyverna Therapeutics, Inc. (0001994702) (Filer)

SEC Filing (8-K) 2026-02-24
kyverna therapeutics
Filed: 2026-02-24 AccNo: 0001193125-26-065320 Size: 196 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Read article

Beam Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Announces New Liver-Targeted Genetic Disease Program in Phenylketonuria (PKU)

beam therapeutics 2026-02-24
phenylketonuria financial results alpha-1 antitrypsin deficiency
New Program Designed as Platform-based Approach for Direct Correction of Mutations Causing PKU; Investigational New Drug (IND) Filing for BEAM‑304 Anticipated in 2026 Updated Phase 1/2 Data and Next Steps for Pivotal Development for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) on Track for Q1
Read article

8-K - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Filer)

SEC Filing (8-K) 2026-02-24
iovance biotherapeutics
Filed: 2026-02-24 AccNo: 0001104659-26-018837 Size: 9 MB Item 2.02: Results of Operations and Financial Condition Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Read article

8-K - Atara Biotherapeutics, Inc. (0001604464) (Filer)

SEC Filing (8-K) 2026-02-23
atara biotherapeutics
Filed: 2026-02-23 AccNo: 0001193125-26-062534 Size: 283 KB Item 1.01: Entry into a Material Definitive Agreement Item 3.02: Unregistered Sales of Equity Securities Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Read article

8-K - Ultragenyx Pharmaceutical Inc. (0001515673) (Filer)

SEC Filing (8-K) 2026-02-23
ultragenyx
Filed: 2026-02-23 AccNo: 0001193125-26-062568 Size: 153 KB Item 8.01: Other Events
Read article

Beam Therapeutics to Host Investor Webcast for Fourth Quarter and Year-End 2025 Financial Results and New Liver-targeted Genetic Disease Program

beam therapeutics 2026-02-23
base editing financial results
CAMBRIDGE, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the company will announce its fourth quarter and full year 2025 financial results and a new
Read article

uniQure N.V. to Report Q4 and Full Year 2025 Financial Results on March 2, 2026

uniQure 2026-02-23
gene therapy financial results
uniQure will announce its 2025 financial results on March 2, 2026, followed by a conference call.Quiver AI SummaryuniQure N.V., a gene therapy company, will release its financial results for the fourth quarter and full year of 2025 on March 2, 2026, prior to market opening. Following the release, management will hold a conference call at 8:00 a.m. ET, which will be available via webcast on the company's website. Analysts can participate in the Q&
Read article

uniQure to Announce 2025 Financial Results

uniQure 2026-02-23
gene therapy financial results
uniQure to host earnings call on Monday, March 2, 2026 at 8:00 a.m. ET ~LEXINGTON, Mass. and AMSTERDAM, Feb. 23, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs will report fourth quarter and full year of 2025 financial results before market open on Monday, March 2, 2026. Management will then host a conference call at 8:00 a.m. ET. The event will be webcast under the Events & Presenta
Read article

Amicus Therapeutics Announces Full-Year 2025 Financial Results and Corporate Updates

amicus therapeutics 2026-02-20
financial results
Read article

Amicus Therapeutics Announces Full-Year 2025 Financial Results and Corporate Updates

BioMarin Pharmaceutical 2026-02-20
financial results
Amicus Therapeutics, a global biotechnology company focused on developing transformative medicines for rare diseases, has released its financial results for the full year ending December 31, 2025. The company reported significant growth in revenue and a strong cash position, alongside notable corpo…
Read article

Mesoblast 2026 Half Year Financial Results Webcast

Mesoblast 2026-02-20
financial results
Read article

PTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results

PR Newswire 2026-02-19
financial results
– Full-year 2025 product and royalty revenue of $831M, exceeding guidance – – Strong Sephience™ (sepiapterin) uptake since 2H 2025 launch with fourth quarter and 2025 revenue of $92M and $111M, respectively – – Cash of $1.95B as of December 31, 2025 – WARREN, N.J., Feb. 19, 2026...
Read article

Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2025 Financial Results and Business Updates

Intellia Therapeutics Inc. 2026-02-19
crispr gene editing financial results
CAMBRIDGE, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that the company will host a conference call on February 26, 2026, at 8 a.m.
Read article

PTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results

ptc biotherapeutics 2026-02-19
financial results
– Full-year 2025 product and royalty revenue of $831M, exceeding guidance – – Strong Sephience™ (sepiapterin) uptake since 2H 2025 launch with fourth quarter and 2025 revenue of $92M and $111M, respectively – – Cash of $1.95B as of December 31, 2025 – WARREN, N.J., Feb.
Read article

Kyowa Kirin : Transcript of Results Briefing Fiscal 2025

Kyowa Kirin 2026-02-19
financial results
Kyowa Kirin Co., Ltd. Financial Results Briefing for the Fiscal Year 2025 February 10, 2026 Event Summary [Event Name] Financial Results Briefing...
Read article

CIMG Inc. Reports Fiscal Year 2025 Financial Results

PR Newswire 2026-02-18
financial results
HONG KONG, Feb. 18, 2026 /PRNewswire/ -- CIMG Inc. ("CIMG" or the "Company") (Nasdaq: IMG), a business group specializing in digital health and sales development, which utilizes technologies and marketing networks to enhance its business partners' sales growth and commercial value, today...
Read article

Krystal Biotech Reports $107.1 Million in 4Q Revenue and FDA Designations for Innovative Gene Therapies

Krystal Biotech 2026-02-17
vyjuvek gene therapies financial results
Krystal Biotech reported $107.1 million in Q4 VYJUVEK revenue, with significant progress in multiple gene therapies and strong financials.Quiver AI SummaryKrystal Biotech, Inc. announced its fourth quarter and full year 2025 financial results, reporting $107.1 million in VYJUVEK revenue for the quarter and a total of $730.3 million since its U.S. launch. The company received an RMAT designation from the FDA for KB707 to treat advanced non-small c
Read article

Cryoport to Report Fourth Quarter and Full Year 2025 Financial Results on March 3, 2026

Cryoport Inc 2026-02-17
financial results
Read article

MIMEDX to Host Fourth Quarter and Full Year 2025 Operating and Financial Results Conference Call on February 25

mimedx 2026-02-17
financial results
MARIETTA, Ga., Feb. 17, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the fourth quarter and full year ended December 31, 2025 after the market close on Wednesday, February 25, 2026.
Read article

BioMarin to Host Fourth Quarter and Full-Year 2025 Financial Results Conference Call and Webcast on Monday, February 23, 2026, at 4: 30pm ET

BioMarin Pharmaceutical 2026-02-17
financial results
SAN RAFAEL, Calif., Feb. 17, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a conference call and...
Read article

BioMarin to Host Fourth Quarter and Full-Year 2025 Financial Results Conference Call and Webcast on Monday, February 23, 2026, at 4:30pm ET

BioMarin Pharmaceutical 2026-02-17
financial results
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a conference call and webcast on Monday, February 23, 2026, at 4:30 p.m. ET to discuss fourth quarter and full-year 2025 financial results and provide a general business update.
Read article

GRAIL to Announce Fourth Quarter and Full Year 2025 Financial Results

PR Newswire 2026-02-16
financial results
MENLO PARK, Calif., Feb. 16, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, announced today that it will issue financial results for the fourth quarter and full year 2025 following the close of market on...
Read article

Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™

PR Newswire 2026-02-13
financial results
Company reports $3.9 million in revenue generated from initial sales in December 2025 and provides first fiscal quarter 2026 financial results CRANFORD, N.J., Feb. 13, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius...
Read article

8-K - Longeveron Inc. (0001721484) (Filer)

SEC Filing (8-K) 2026-02-13
longeveron
Filed: 2026-02-13 AccNo: 0001213900-26-016519 Size: 319 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 9.01: Financial Statements and Exhibits
Read article

Perrigo to Release Fourth Quarter and Fiscal Year 2025 Financial Results on February 26, 2026

PR Newswire 2026-02-13
financial results
DUBLIN, Feb. 13, 2026 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of consumer health products, today announced that it plans to issue its fourth quarter and fiscal year 2025 financial results on Thursday, February 26th, 2026, and host a conference call beginning...
Read article

Vertex Reports Fourth Quarter and Full Year 2025 Financial Results

Vertex 2026-02-12
financial results
— Full year total revenue of $12.0 billion, a 9% increase compared to full year 2024; fourth quarter total revenue of $3.19 billion, a 10% increase compared to fourth quarter 2024 — — Company provides full year 2026 total revenue guidance of $12.95 billion to $13.1 billion, with non-CF products
Read article

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

CRISPR 2026-02-12
crispr financial results
ZUG, Switzerland and BOSTON, Feb. 12, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the fourth quarter and full year ended December 31, 2025. “As we close out the fourth quarter, CRISPR Therapeutics continues to make steady progress across a broad
Read article

Ultragenyx Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Update—Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical 2026-02-12
financial results
The Investor Relations website contains information about Ultragenyx Pharmaceutical Inc.'s business for stockholders, potential investors, and financial analysts.
Read article

Benitec Biopharma Releases Second Quarter 2026 Financial Results and Provides Operational Update

benitec biopharma 2026-02-12
financial results
Read article

Iovance Biotherapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Updates on Tuesday, February 24, 2026

Iovance Biotherapeutics 2026-02-11
financial results
SAN CARLOS, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will host a conference call and live
Read article

Medtronic to announce financial results for its third quarter of fiscal year 2026

PR Newswire 2026-02-11
financial results
GALWAY, Ireland, Feb. 11, 2026 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that it will report financial results on Tuesday, February 17, 2026, for its third quarter of fiscal year 2026, which ended on Friday, January 23, 2026. A...
Read article

Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2025 Financial Results

Sarepta Therapeutics 2026-02-11
financial results
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 11, 2026-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report fourth quarter and full-year 2025 financial results after the Nasdaq Global Market closes on Wednesday, Feb. 25, 2026.
Read article

Gilead Sciences 4th-qtr beats expectations but guidance disappoints

Gilead Sciences 2026-02-11
financial results
US antivirals giant Gilead Sciences posted fourth quarter and full year 2025 financial results yesterday that received a mixed market reaction.
Read article

Gilead Sciences Announces Fourth Quarter and Full Year 2025 Financial Results

Gilead Sciences 2026-02-10
financial results
Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the fourth quarter and full year 2025. “Our fourth quarter and full-year r...
Read article

Gilead Sciences Announces Fourth Quarter and Full Year 2025 Financial Results

Gilead Sciences 2026-02-10
financial results
Gilead Sciences, Inc., a biopharmaceutical company known for its innovative treatments for life-threatening diseases, has released its financial results for the fourth quarter and full year 2025. The company reported strong performance across several key metrics, reflecting its robust market positi…
Read article

Axogen, Inc. to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026

axogen 2026-02-10
financial results
Read article

Axogen, Inc. to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026

axogen 2026-02-10
financial results
Read article

AstraZeneca raises guidance on stellar cancer drugs growth

PharmaPhorum 2026-02-10
financial results
AZ reports strong financial results for 2025, and provides a first peek at the data for its oral GLP-1 contender elecoglipron.
Read article

Announcement of Consolidated Financial Results Fiscal 2025

Kyowa Kirin Co. 2026-02-09
financial results
Read article

8-K - Ocugen, Inc. (0001372299) (Filer)

SEC Filing (8-K) 2026-02-09
ocugen
Filed: 2026-02-09 AccNo: 0001104659-26-011765 Size: 283 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Read article

Bioretec Ltd's financial statements bulletin for January-December 2025 will be published on February 13, 2026

PR Newswire 2026-02-09
financial statements
TAMPERE, Finland, Feb. 9, 2026 /PRNewswire/ -- Bioretec Ltd will publish its financial statements bulletin for the financial year 1 January-31 December 2025 on Friday, 13 February 2026 at approximately 9:30 a.m. EET. The company will arrange a webcast for investors and media on the same...
Read article

Kaiser Permanente and Risant Health report 2025 financial results

PR Newswire 2026-02-06
financial results
The organizations delivered high-quality, affordable, value-based care for members and patients and worked to improve the health of the communities they serve. OAKLAND, Calif., Feb. 6, 2026 /PRNewswire/ -- Kaiser Foundation Health Plan, Inc., Kaiser Foundation Hospitals, Risant Health,...
Read article

Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2025 Financial Results and Corporate Update—Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical 2026-02-05
financial results
The Investor Relations website contains information about Ultragenyx Pharmaceutical Inc.'s business for stockholders, potential investors, and financial analysts.
Read article

PTC Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, Feb. 19, 2026

ptc biotherapeutics 2026-02-05
financial results
WARREN, N.J., Feb. 5, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the company will host a webcast conference call to report its fourth quarter and full year 2025 financial results and provide an update on the company's business and outlook on Thursday, Feb.
Read article

AbbVie Reports Full-Year and Fourth-Quarter 2025 Financial Results

Abbvie Investors 2026-02-04
financial results
Reports Full-Year Diluted EPS of $2.36 on a GAAP Basis, a Decrease of 1.3 Percent; Adjusted Diluted EPS of $10.00, a Decrease of 1.2 Percent; These Results Include an Unfavorable Impact of $2.76 Per Share Related to 2025 Acquired IPR&D and Milestones Expense Delivers Full-Year Net Revenues of
Read article

Evolent To Release 2025 Fourth Quarter and Year-End Financial Results on Tuesday, February 24, 2026

PR Newswire 2026-02-04
financial results
WASHINGTON, Feb. 4, 2026 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company focused on achieving better health outcomes for people with complex conditions, today announced it will release its 2025 fourth quarter and year-end financial results on Tuesday, February 24, 2026, after...
Read article

Financial Results of Astellas for Q3 YTD/FY2025

astellas 2026-02-04
financial results
View Financial Results of Astellas for Q3 YTD/FY2025.
Read article

GSK delivers in new CEO Miels' first financial update

PharmaPhorum 2026-02-04
financial results
Luke Miels' first financial results since taking over as chief executive of GSK revealed a jump in sales and profits.
Read article

8-K - Ultragenyx Pharmaceutical Inc. (0001515673) (Filer)

SEC Filing (8-K) 2026-02-03
ultragenyx
Filed: 2026-02-03 AccNo: 0001193125-26-034474 Size: 174 KB Item 8.01: Other Events
Read article

8-K - Kyverna Therapeutics, Inc. (0001994702) (Filer)

SEC Filing (8-K) 2026-02-03
kyverna therapeutics
Filed: 2026-02-03 AccNo: 0001193125-26-034464 Size: 422 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Read article

8-K - Ultragenyx Pharmaceutical Inc. (0001515673) (Filer)

SEC Filing (8-K) 2026-01-30
ultragenyx
Filed: 2026-01-30 AccNo: 0001193125-26-030590 Size: 155 KB Item 8.01: Other Events
Read article

LYMA REPORTS STRONG 2025 PERFORMANCE WITH $48M REVENUE AS US EXPANSION DRIVES GROWTH

PR Newswire 2026-01-29
financial results
NEW YORK, Jan. 29, 2026 /PRNewswire/ -- LYMA, the luxury regenerative MedTech company, today revealed its financial results for the year ending 31 December 2025, reporting revenues of $48 million and EBITDA of $7 million, marking a year of significant growth driven by successful expansion...
Read article

Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025 and Provide Business Update on Thursday, May 29, 2025

roivant 2026-01-28
financial results
BASEL, Switzerland and LONDON and NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, May 29, 2025, to report its financial results for the fourth quarter and fiscal year ended March 31,
Read article

Gilead Sciences to Release Fourth Quarter & Full Year 2025 Financial Results on Tuesday, February 10, 2026

Gilead Sciences 2026-01-28
financial results
Read article

8-K - REGENXBIO Inc. (0001590877) (Filer)

SEC Filing (8-K) 2026-01-28
regenxbio
Filed: 2026-01-28 AccNo: 0001193125-26-026139 Size: 205 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Read article

8-K - Intellia Therapeutics, Inc. (0001652130) (Filer)

SEC Filing (8-K) 2026-01-27
intellia therapeutics
Filed: 2026-01-27 AccNo: 0001193125-26-023387 Size: 189 KB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Read article

Gilead Sciences to Release Fourth Quarter & Full Year 2025 Financial Results on Tuesday, February 10, 2026

Gilead Sciences 2026-01-27
financial results
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its fourth quarter and full year 2025 financial results and guidance will be released on Tuesday, F...
Read article

8-K - BIOMARIN PHARMACEUTICAL INC (0001048477) (Filer)

SEC Filing (8-K) 2026-01-26
biomarin pharmaceutical
Filed: 2026-01-26 AccNo: 0001193125-26-021718 Size: 573 KB Item 2.02: Results of Operations and Financial Condition Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Read article

Roivant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026

roivant 2026-01-23
financial results
BASEL, Switzerland and LONDON and NEW YORK, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Friday, February 6, 2026, to report its financial results for the second quarter ended December 31, 2026, and
Read article

8-K - Ocugen, Inc. (0001372299) (Filer)

SEC Filing (8-K) 2026-01-23
ocugen
Filed: 2026-01-23 AccNo: 0001104659-26-006031 Size: 213 KB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Read article

8-K - enGene Holdings Inc. (0001980845) (Filer)

SEC Filing (8-K) 2026-01-21
engene
Filed: 2026-01-21 AccNo: 0001193125-26-017226 Size: 250 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Read article

8-K - Ocugen, Inc. (0001372299) (Filer)

SEC Filing (8-K) 2026-01-21
ocugen
Filed: 2026-01-21 AccNo: 0001104659-26-005454 Size: 535 KB Item 1.01: Entry into a Material Definitive Agreement Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Read article

Waters Corporation Schedules Fourth Quarter 2025 Earnings Conference Call

PR Newswire 2026-01-20
financial results
MILFORD, Mass., Jan. 20, 2026 /PRNewswire/ -- Waters Corporation (NYSE:WAT) will hold its Q4 2025 financial results conference call on Thursday, February 12th, 2026 at 8:00 a.m. Eastern Time. A live webcast of the presentation will be available on Waters Investor Relations website at...
Read article

Vertex to Announce Fourth Quarter and Full Year 2025 Financial Results on February 12th

Vertex 2026-01-20
financial results
BOSTON --(BUSINESS WIRE)--Jan. 20, 2026-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its fourth quarter and full year 2025 financial results on Thursday, February 12, 2026 , after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET .
Read article

8-K - Sarepta Therapeutics, Inc. (0000873303) (Filer)

SEC Filing (8-K) 2026-01-12
sarepta therapeutics
Filed: 2026-01-12 AccNo: 0001193125-26-010116 Size: 234 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read article

Krystal Biotech Reports ~$389M 2025 VYJUVEK Revenue, $955M Cash Reserves

Krystal Biotech 2026-01-12
vyjuvek financial results
(RTTNews) - Krystal Biotech Inc. (KRYS) announced preliminary unaudited financial results for 2025, including strong performance from its lead product VYJUVEK, and shared its strategic vision for advancing rare disease therapies.
Read article

8-K - BRISTOL MYERS SQUIBB CO (0000014272) (Filer)

SEC Filing (8-K) 2026-01-12
bristol myers squibb
Filed: 2026-01-12 AccNo: 0001140361-26-000929 Size: 3 MB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Read article

8-K - PTC THERAPEUTICS, INC. (0001070081) (Filer)

SEC Filing (8-K) 2026-01-12
ptc therapeutics
Filed: 2026-01-12 AccNo: 0001104659-26-002799 Size: 4 MB Item 2.02: Results of Operations and Financial Condition Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Read article

Krystal Biotech Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference

Krystal Biotech 2026-01-11
vyjuvek financial results
Preliminary 4Q 2025 VYJUVEK net revenue of $106 million to $107 million Robust clinical pipeline with multibillion dollar opportunities and strong balance sheet for sustained growth PITTSBURGH, Jan. 11, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) today announced selected preliminary unaudited 2025 financial results, including fourth quarter and full year 2025 VYJUVEK® net product revenue, and outlined the Company’s strategic vision to drive the next stage of gro
Read article

8-K - uniQure N.V. (0001590560) (Filer)

SEC Filing (8-K) 2026-01-09
uniqure
Filed: 2026-01-09 AccNo: 0001104659-26-002317 Size: 169 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Read article

8-K - Intellia Therapeutics, Inc. (0001652130) (Filer)

SEC Filing (8-K) 2026-01-09
intellia therapeutics inc.
Filed: 2026-01-09 AccNo: 0001193125-26-008307 Size: 5 MB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Read article

8-K - CG Oncology, Inc. (0001991792) (Filer)

SEC Filing (8-K) 2026-01-09
cg oncology
Filed: 2026-01-09 AccNo: 0001193125-26-008329 Size: 15 MB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Read article

8-K - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Filer)

SEC Filing (8-K) 2026-01-09
iovance biotherapeutics
Filed: 2026-01-09 AccNo: 0001104659-26-002323 Size: 8 MB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Read article

CVS Health to hold fourth quarter and full year 2025 earnings conference call

PR Newswire 2026-01-09
financial results
WOONSOCKET, R.I., Jan. 9, 2026 /PRNewswire/ -- CVS Health® (NYSE: CVS) will hold a conference call with analysts and investors on Wednesday, February 11th, 2026, at 8:00 a.m. ET to discuss fourth quarter and full year 2025 financial results. An audio webcast of the event will be broadcast...
Read article

Quest Diagnostics to Release Fourth Quarter and Full Year 2025 Financial Results on February 10, 2026

PR Newswire 2026-01-08
financial results
SECAUCUS, N.J., Jan. 8, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, today announced that it will report fourth quarter and full year 2025 financial results on Tuesday, February 10, 2026, before the market opens. It will...
Read article

8-K - 4D Molecular Therapeutics, Inc. (0001650648) (Filer)

SEC Filing (8-K) 2026-01-07
4d molecular therapeutics
Filed: 2026-01-07 AccNo: 0001193125-26-005470 Size: 164 KB Item 2.02: Results of Operations and Financial Condition Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Read article

LENZ Therapeutics Reports Fourth Quarter 2025 Preliminary Unaudited Financial Results and Recent Corporate Updates

LENZ Therapeutics 2026-01-07
financial results
Read article

AbbVie to Host Full-Year and Fourth-Quarter 2025 Earnings Conference Call

Abbvie Investors 2026-01-07
financial results
NORTH CHICAGO, Ill. , Jan. 7, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its full-year and fourth-quarter 2025 financial results on Wednesday, February 4, 2026 , before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time .
Read article

8-K - Ultragenyx Pharmaceutical Inc. (0001515673) (Filer)

SEC Filing (8-K) 2025-12-29
ultragenyx
Filed: 2025-12-29 AccNo: 0001193125-25-332422 Size: 157 KB Item 8.01: Other Events
Read article

Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update

PR Newswire 2025-12-23
financial results
Subsidiary, Citius Oncology, launches cancer immunotherapy, LYMPHIR™, in the U.S. in December 2025 CRANFORD, N.J., Dec. 23, 2025 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and...
Read article

Citius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update

PR Newswire 2025-12-23
financial results
Cancer Immunotherapy, LYMPHIR™, launched in the U.S. in December 2025 Completed $36 million in strategic financings, of which $18 million was via private placement and concurrent registered direct offering on December 10, 2025, to strengthen cash position and support continued...
Read article

8-K - Krystal Biotech, Inc. (0001711279) (Filer)

SEC Filing (8-K) 2025-12-23
krystal biotech
Filed: 2025-12-23 AccNo: 0001711279-25-000092 Size: 138 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 9.01: Financial Statements and Exhibits
Read article

enGene Reports Full Year 2025 Financial Results and Provides Business Update

enGene Google 2025-12-23
financial results
Read article

Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2025 Financial Results

Sangamo BioSciences 2025-12-22
financial results
The Investor Relations website contains information about Sangamo Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts.
Read article

Bioretec Ltd's schedule for financial reporting and Annual General Meeting in 2026

PR Newswire 2025-12-22
financial statements
Bioretec Ltd Company announcement 22 December 2025 at 5:30 p.m. EET TAMPERE, Finland, Dec. 22, 2025 /PRNewswire/ -- In 2025, Bioretec will publish the following financial reports: financial statements bulletin for January-December 2025 on Friday 13 February 2025 annual report, Board of...
Read article

8-K - BIOMARIN PHARMACEUTICAL INC (0001048477) (Filer)

SEC Filing (8-K) 2025-12-22
biomarin pharmaceutical
Filed: 2025-12-22 AccNo: 0001193125-25-327828 Size: 131 KB Item 8.01: Other Events
Read article

Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2025 Financial Results

Sangamo BioSciences 2025-12-22
financial results
The Investor Relations website contains information about Sangamo Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts.
Read article

Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2025 Financial Results

Sangamo BioSciences 2025-12-21
financial results
The Investor Relations website contains information about Sangamo Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts.
Read article

Tokyo Lifestyle Co., Ltd. Reports First Six Months of Fiscal Year 2026 Financial Results

PR Newswire 2025-12-19
financial results
Revenue Increased by 94.3% YoY; Gross Profit Increased by 29.8% YoY TOKYO, Dec. 19, 2025 /PRNewswire/ -- Tokyo Lifestyle Co., Ltd. ("Tokyo Lifestyle" or the "Company") (Nasdaq: TKLF), a retailer and wholesaler of Japanese beauty and health products, sundry products, luxury products,...
Read article

8-K - BIOMARIN PHARMACEUTICAL INC (0001048477) (Filer)

SEC Filing (8-K) 2025-12-19
biomarin pharmaceutical
Filed: 2025-12-19 AccNo: 0001193125-25-325856 Size: 1 MB Item 1.01: Entry into a Material Definitive Agreement Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Read article

8-K - Kyverna Therapeutics, Inc. (0001994702) (Filer)

SEC Filing (8-K) 2025-12-15
kyverna therapeutics
Filed: 2025-12-15 AccNo: 0001193125-25-318469 Size: 10 MB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Read article

8-K - Sarepta Therapeutics, Inc. (0000873303) (Filer)

SEC Filing (8-K) 2025-12-11
sarepta therapeutics
Filed: 2025-12-11 AccNo: 0001193125-25-315032 Size: 166 KB Item 3.02: Unregistered Sales of Equity Securities Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Read article

Memorial Healthcare System Reports Strong First-Half Financial Results, Reinforcing Commitment to Community Investment

PR Newswire 2025-12-08
financial results
HOLLYWOOD, Fla., Dec. 8, 2025 /PRNewswire/ -- Memorial Healthcare System reported strong financial results for the first half of fiscal year 2025, reflecting continued growth, disciplined management, and an enduring commitment to reinvesting in the community. Through the first six months...
Read article

REGENXBIO Reports Second Quarter 2025 Financial Results and Operational Highlights

REGENXBIO 2025-12-04
financial results
Read article

REGENXBIO to Host Conference Call on August 7 to Discuss Second Quarter 2025 Financial Results and Operational Highlights

REGENXBIO 2025-12-04
financial results
Read article

8-K - uniQure N.V. (0001590560) (Filer)

SEC Filing (8-K) 2025-12-04
uniqure
Filed: 2025-12-04 AccNo: 0001104659-25-118292 Size: 180 KB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Read article

Financial Results of Astellas for Q2 YTD/FY2025

astellas 2025-12-04
financial results
Read article

Adicet Bio Reports Second Quarter 2025 Financial Results and Provides Business Updates

Adicet Bio 2025-12-04
financial results
Read article

Adicet Bio Reports Third Quarter 2025 Financial Results and Provides Business Updates

Adicet Bio 2025-12-04
financial results
Read article

8-K - CAPRICOR THERAPEUTICS, INC. (0001133869) (Filer)

SEC Filing (8-K) 2025-12-03
capricor therapeutics
Filed: 2025-12-03 AccNo: 0001104659-25-117947 Size: 211 KB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Read article

8-K - CAPRICOR THERAPEUTICS, INC. (0001133869) (Filer)

SEC Filing (8-K) 2025-12-03
capricor therapeutics
Filed: 2025-12-03 AccNo: 0001104659-25-117981 Size: 2 MB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Read article

Innocan Pharma Reports Financial Results for Q3 2025, with Revenues at US $21.6M

PR Newswire 2025-11-27
financial results
HERZLIYA, Israel and CALGARY, AB, Nov. 27, 2025 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan"), a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies, is pleased to announce...
Read article

Devonian Health Group Reports its Fourth Quarter and Annual 2025 Financial Results and Appointment of a New Board Member

PR Newswire 2025-11-26
financial results
Fourth quarter distribution revenues of $1.3 million Fourth quarter net loss of $0.4 million, $0.003 per share Annual distribution revenues of $23.6 million Annual net loss of $6 million, $0.041 per share Devonian is debt free with $7 million in cash as of July 31, 2025 Pierre Labbé...
Read article

8-K - CG Oncology, Inc. (0001991792) (Filer)

SEC Filing (8-K) 2025-11-26
cg oncology
Filed: 2025-11-26 AccNo: 0001193125-25-298160 Size: 162 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Read article

How Investors May Respond To CG Oncology (CGON) Leadership Transition Amid Rising Revenue and Expanding Losses

CG Oncology 2025-11-23
financial results
On November 14, 2025, CG Oncology reported its third quarter and nine-month financial results, highlighting a significant year-over-year increase in revenue to US$1.67 million and US$1.72 million respectively, but with a wider net loss for both periods. In addition, the company announced the appointment of Jim DeTore as interim principal financial and accounting officer effective November 17, signifying a transition in leadership amid financial changes. We'll examine how the arrival of a new...
Read article

CG Oncology (CGON): Valuation Insights Following Strong Revenue Growth and Widening Losses in Latest Results

CG Oncology 2025-11-22
quarterly financial results
CG Oncology (CGON) has just released its latest quarterly and nine-month financial results, showing revenue growth compared to a year ago, even as net losses widened. This update offers a fresh angle for investors tracking CGON’s momentum and financial health. See our latest analysis for CG Oncology. After rallying strongly through the last quarter, CG Oncology’s share price has climbed 57.7% over the past 90 days and sits at $42.44. This momentum has sparked wider interest, even as the...
Read article

Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2022 Financial Results

Sangamo BioSciences 2025-11-21
financial results
The Investor Relations website contains information about Sangamo Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts.
Read article

Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2022 Financial Results

Sangamo BioSciences 2025-11-21
financial results
The Investor Relations website contains information about Sangamo Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts.
Read article

Adicet Bio Reports First Quarter 2025 Financial Results and Provides Business Updates

Adicet Bio 2025-11-19
financial results
Read article

Amicus Therapeutics Announces Second Quarter 2025 Financial Results and Corporate Updates

amicus therapeutics 2025-11-18
financial results
Read article

8-K - BRISTOL MYERS SQUIBB CO (0000014272) (Filer)

SEC Filing (8-K) 2025-11-18
bristol myers squibb
Filed: 2025-11-18 AccNo: 0001140361-25-042607 Size: 937 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Read article

Amicus Therapeutics to Announce Second Quarter 2025 Financial Results on July 31, 2025

amicus therapeutics 2025-11-18
financial results
Read article

Amicus Therapeutics Announces Third Quarter 2025 Financial Results and Corporate Updates

amicus therapeutics 2025-11-18
financial results
Read article

Amicus Therapeutics to Announce Third Quarter 2025 Financial Results on November 4, 2025

amicus therapeutics 2025-11-18
financial results
Read article

Benitec Biopharma Releases First Quarter 2026 Financial Results and Provides Operational Update

benitec biopharma 2025-11-14
financial results
Read article

8-K - CG Oncology, Inc. (0001991792) (Filer)

SEC Filing (8-K) 2025-11-14
cg oncology
Filed: 2025-11-14 AccNo: 0001193125-25-281672 Size: 405 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read article

[8-K] CG Oncology, Inc. Reports Material Event

CG Oncology 2025-11-14
financial results
CG Oncology (CGON) furnished an update on its financial results under Item 2.02. The company announced it issued a press release covering results for the quarte
Read article

BrainStorm Cell Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update

BrainStorm Cell Therapeutics 2025-11-14
financial results
Read article

Elicio Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Updates

Elicio Therapeutics 2025-11-13
financial results
November 13, 2025 16:01 ETIn the ongoing Phase 2 AMPLIFY-7P study evaluating ELI-002 7P in patients with pancreatic ductal adenocarcinoma (“PDAC”), ...
Read article

Century Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Century Therapeutics 2025-11-13
financial results
Read article

Vor Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Vor Biopharma 2025-11-13
financial results
Multiple Late-Stage Data Readouts Reinforce Telitacicept’s Broad Potential Across Autoimmune Diseases Expansion of Executive Leadership and Board Strengthens Global Development Capabilities Expected gross proceeds of $115 million raised in the November 2025 underwritten public offering, including
Read article

8-K - Atara Biotherapeutics, Inc. (0001604464) (Filer)

SEC Filing (8-K) 2025-11-12
atara biotherapeutics
Filed: 2025-11-12 AccNo: 0001193125-25-276209 Size: 228 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read article

Atara Biotherapeutics Announces Third Quarter Financial Results and Operational Progress

Atara Biotherapeutics 2025-11-12
financial results
Read article

Abeona Therapeutics® Reports Third Quarter 2025 Financial Results and Corporate Updates

Abeona Therapeutics 2025-11-12
financial results
Read article

Venture Global (VG): Assessing Valuation Following Ongoing Share Price Decline

uniQure 2025-11-12
financial results
Venture Global (VG) shares moved lower this week, continuing a trend that has seen the stock fall 45% over the past 3 months. Investors remain focused on the company’s recent financial results and evolving growth outlook. See our latest analysis for Venture Global. Venture Global's recent slide comes after a tough stretch this year, with the share price return now down 68.6% year-to-date and momentum clearly fading. A string of weaker financial updates and cautious investor sentiment seem to...
Read article

Opus Genetics Announces Financial Results for Third Quarter 2025 and Provides Corporate Update

opus genetics 2025-11-12
financial results
Read article

10-Q - Atara Biotherapeutics, Inc. (0001604464) (Filer)

SEC Filing (10-Q) 2025-11-12
atara biotherapeutics
Filed: 2025-11-12 AccNo: 0001193125-25-276219 Size: 12 MB
Read article

Autolus Therapeutics : 251112 Q3 2025 Earnings Final v2

Autolus Therapeutics 2025-11-12
financial results
Q3 2025 Financial Results and Business Updates November 12, 2025 For Investor communication only. Not for use in product promotion. Not for further...
Read article

8-K - Intellia Therapeutics, Inc. (0001652130) (Filer)

SEC Filing (8-K) 2025-11-10
intellia therapeutics inc.
Filed: 2025-11-10 AccNo: 0001193125-25-274596 Size: 238 KB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Read article

Cabaletta Bio Reports Third Quarter 2025 Financial Results and Provides Business Update

cabaletta bio 2025-11-10
financial results
Read article

INOVIO Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Inovio Pharmaceuticals 2025-11-10
financial results
Read article

10-Q - CAPRICOR THERAPEUTICS, INC. (0001133869) (Filer)

SEC Filing (10-Q) 2025-11-10
capricor therapeutics
Filed: 2025-11-10 AccNo: 0001104659-25-109298 Size: 7 MB
Read article

Passage Bio Reports Third Quarter 2025 Financial Results and Provides Recent Business Highlights

passage bio 2025-11-10
financial results
Read article

Capricor Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Capricor Therapeutics 2025-11-10
financial results
Read article

Celldex Reports Third Quarter 2025 Financial Results and Provides Corporate UpdateDownload PDF

Celldex Therapeutics 2025-11-10
financial results
Strong execution and continued progress across pipeline Positive Phase 2 barzolvolimab data in Chronic Spontaneous Urticaria (CSU) demonstrating rapid, profound improvement in UCT7 scores with sustained disease control post treatment and strong efficacy regardless of baseline IgE levels Positive Download PDF
Read article

Roivant Reports Financial Results for the Second Quarter Ended September 30, 2025, and Provides Business Update

roivant 2025-11-10
financial results
BASEL, Switzerland and LONDON and NEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today reported its financial results for the second quarter ended September 30, 2025, and provided a business update. Brepocitinib 30 mg demonstrated clinically meaningful and statistically
Read article

Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results

Cullinan Therapeutics 2025-11-07
financial results
Read article

Abeona Therapeutics® Announces Date of Third Quarter Financial Results and Upcoming Investor Conference Participation

Abeona Therapeutics 2025-11-07
financial results
Read article

Lisata Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Lisata Therapeutics 2025-11-06
financial results
Data rich period continues to support certepetide’s broad applicability and effectiveness Catalent enters into global license agreement for the use of certepetide as part of their SMARTag® Antibody-Drug Conjugate Technology Platform Strategic Alliance formed with GATC Health to exploit their
Read article

Humacyte to Present Third Quarter Financial Results and Provide Business Update on November 12, 2025

Humacyte 2025-11-06
financial results
DURHAM, N.C. , Nov. 06, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, will release its financial results for the quarter ended September 30, 2025 , on
Read article

MiNK Therapeutics to Report Third Quarter 2025 Financial Results and Highlight Clinical and Corporate Milestones Advancing iNKT Platform Toward Pivotal Development

Mink Therapeutics 2025-11-06
pivotal allogeneic cell therapies financial results
NEW YORK , Nov. 05, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics , Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and immune disorders, today announced that the Company will release its third
Read article

Lexeo Therapeutics Reports Third Quarter 2025 Financial Results and Operational Highlights

Lexeo Therapeutics 2025-11-06
financial results
Read article

LENZ Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

LENZ Therapeutics 2025-11-05
financial results
Read article

Cryoport Reports Third Quarter 2025 Financial Results

Cryoport Inc 2025-11-04
financial results
Read article

Lisata Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Business Update on Thursday, August 7, 2025

Lisata Therapeutics 2025-11-04
financial results
BASKING RIDGE, N.J., July 31, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that the
Read article

Taysha Gene Therapies Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Taysha Gene Therapies 2025-11-04
bla pivotal phase 1/2 gene therapies financial results breakthrough therapy
TSHA-102 granted Breakthrough Therapy designation by FDA Finalized FDA alignment on REVEAL pivotal trial protocol and SAP, including 6-month interim analysis that may expedite BLA submission, which was enabled by the rigorous developmental milestone evaluation in Part A REVEAL Phase 1/2 trials
Read article

Ultragenyx Reports Third Quarter 2025 Financial Results and Corporate Update—Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical 2025-11-04
financial results
The Investor Relations website contains information about Ultragenyx Pharmaceutical Inc.'s business for stockholders, potential investors, and financial analysts.
Read article

10-Q - Krystal Biotech, Inc. (0001711279) (Filer)

SEC Filing (10-Q) 2025-11-03
krystal biotech
Filed: 2025-11-03 AccNo: 0001711279-25-000087 Size: 6 MB
Read article

AbbVie Reports Third-Quarter 2025 Financial Results

Abbvie Investors 2025-10-31
financial results
Reports Third-Quarter Diluted EPS of $0.10 on a GAAP Basis, a Decrease of 88.6 Percent; Adjusted Diluted EPS of $1.86 , a Decrease of 38.0 Percent; These Results Include an Unfavorable Impact of $1.50 Per Share Related to Acquired IPR&D and Milestones Expense Delivers Third-Quarter Net Revenues
Read article

Capricor Therapeutics to Present Third Quarter 2025 Financial Results and Recent Corporate Update on November 10

Capricor Therapeutics 2025-10-31
financial results
Read article

10-Q - BRISTOL MYERS SQUIBB CO (0000014272) (Filer)

SEC Filing (10-Q) 2025-10-30
bristol myers squibb
Filed: 2025-10-30 AccNo: 0000014272-25-000149 Size: 13 MB
Read article

Financial Results of Astellas for Q2 YTD/FY2025

astellas 2025-10-30
financial results
View Financial Results of Astellas for Q2 YTD/FY2025.
Read article

Announcement of Consolidated Financial Results Fiscal 2025 Third Quarter

Kyowa Kirin Co. 2025-10-30
financial results
Read article

8-K - Ultragenyx Pharmaceutical Inc. (0001515673) (Filer)

SEC Filing (8-K) 2025-10-30
ultragenyx
Filed: 2025-10-30 AccNo: 0001193125-25-257538 Size: 170 KB Item 8.01: Other Events
Read article

Lisata Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Business Update on Thursday, November 6, 2025

Lisata Therapeutics 2025-10-30
financial results
BASKING RIDGE, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that the
Read article

Autolus Therapeutics to Report Third Quarter 2025 Financial Results and Host Conference Call on November 12, 2025

Autolus Therapeutics 2025-10-30
financial results
LONDON & GAITHERSBURG, Md., Oct. 30, 2025 -- Autolus Therapeutics plc , an early commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T...
Read article

Axogen, Inc. Reports Third Quarter 2025 Financial Results

axogen 2025-10-29
financial results
Read article

Axogen, Inc. Reports Third Quarter 2025 Financial Results

axogen 2025-10-29
financial results
Read article

LENZ Therapeutics to Report Third Quarter 2025 Financial Results and Recent Corporate Highlights on November 5, 2025

LENZ Therapeutics 2025-10-29
financial results
Read article

Taysha Gene Therapies to Release Third Quarter 2025 Financial Results and Host Conference Call and Webcast on November 4

Taysha Gene Therapies 2025-10-28
aav gene therapies financial results adeno-associated virus
DALLAS , Oct. 28, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today
Read article

Ultragenyx to Host Conference Call for Third Quarter 2025 Financial Results and Corporate Update—Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical 2025-10-28
financial results
The Investor Relations website contains information about Ultragenyx Pharmaceutical Inc.'s business for stockholders, potential investors, and financial analysts.
Read article

INOVIO to Report Third Quarter 2025 Financial Results on November 10, 2025

Inovio Pharmaceuticals 2025-10-27
financial results
Read article

Roivant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025

roivant 2025-10-27
financial results
BASEL, Switzerland and LONDON and NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Monday, November 10, 2025, to report its financial results for the second quarter ended September 30, 2025,
Read article

Cryoport to Report Third Quarter 2025 Financial Results on November 4, 2025

Cryoport Inc 2025-10-21
financial results
Read article

PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2025 Financial Results

ptc biotherapeutics 2025-10-21
financial results
WARREN, N.J. , Oct. 21, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the company will host a webcast conference call to report its third quarter 2025 financial results and provide an update on the company's business and outlook on Tuesday, November 4 , at 4:30
Read article

Axogen, Inc. to Report 2025 Third Quarter Financial Results on October 29, 2025

axogen 2025-10-15
financial results
Read article

MIMEDX to Host Third Quarter 2025 Operating and Financial Results Conference Call on October 29

mimedx 2025-10-15
financial results
MARIETTA, Ga., Oct. 15, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the third quarter ended September 30, 2025 after the market close on Wednesday, October 29, 2025.
Read article

Vertex to Announce Third Quarter 2025 Financial Results on November 3rd

Vertex 2025-10-06
financial results
BOSTON --(BUSINESS WIRE)--Oct. 6, 2025-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third quarter 2025 financial results on Monday, November 3, 2025 , after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET .
Read article

AbbVie to Host Third-Quarter 2025 Earnings Conference Call

Abbvie Investors 2025-10-02
financial results
NORTH CHICAGO, Ill. , Oct. 2, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its third-quarter 2025 financial results on Friday, October 31, 2025 , before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time .
Read article

GenSight Biologics Reports Interim Financial Results for the First Half of 2025

GenSight Biologics 2025-09-30
financial results
Read article

GenSight Biologics Reports Interim Financial Results for the First Half of 2025

GenSight Biologics 2025-09-30
financial results
Read article

Celyad Oncology reports first half year 2025 financial results

Celyad 2025-09-25
financial results
Mont-Saint-Guibert, Belgium; September 25, 2025, 6:30 pm CET; regulated information – Celyad Oncology (Euronext: CYAD) (the “Company”), today announced its […] The post Celyad Oncology reports first half year 2025 financial results appeared first on .
Read article

Benitec Biopharma Releases Full Year 2025 Financial Results and Provides Operational Update

benitec biopharma 2025-09-22
financial results
Read article

GenSight Biologics Postpones Release of 2025 Half-Year Financial Results

GenSight Biologics 2025-08-29
financial results
Read article

GenSight Biologics Postpones Release of 2025 Half-Year Financial Results

GenSight Biologics 2025-08-29
financial results
Read article

Lexeo Therapeutics Reports Second Quarter 2025 Financial Results and Operational Highlights

Lexeo Therapeutics 2025-08-15
financial results
Read article

Century Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Century Therapeutics 2025-08-14
financial results
Read article

Abeona Therapeutics® Reports Second Quarter 2025 Financial Results and Corporate Updates

Abeona Therapeutics 2025-08-14
financial results
Read article

BrainStorm Cell Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate Update

BrainStorm Cell Therapeutics 2025-08-14
financial results
Read article

Tourmaline Bio Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Talaris Therapeutics 2025-08-13
quarterly financial results
– Reported positive topline results from the ongoing Phase 2 TRANQUILITY trial of pacibekitug in May 2025, demonstrating rapid, deep, and durable reductions in high-sensitivity C-reactive protein with quarterly dosing – — Additional data from the ongoing Phase 2 TRANQUILITY trial to be presented at
Read article

Taysha Gene Therapies Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Taysha Gene Therapies 2025-08-12
pivotal gene therapies financial results
Commenced site activation for REVEAL pivotal trial in accordance with previously aligned upon key design elements, following receipt of No Objection Letter (NOL) from Health Canada and feedback from the FDA; patient enrollment anticipated to begin in Q4 2025 High dose and low dose TSHA-102 continue
Read article

Caribou Biosciences Reports Second Quarter 2025 Financial Results and Provides Business Update

caribou biosciences 2025-08-12
financial results
Two robust clinical datasets from CB-010 and CB-011 expected to be disclosed in H2 2025 -- -- $184 million in cash, cash equivalents, and marketable securities expected to fund the Company’s current operating plan into H2 2027 -- BERKELEY, Calif., Aug.
Read article

Passage Bio Reports Second Quarter 2025 Financial Results and Provides Recent Business Highlights

passage bio 2025-08-12
financial results
Read article

Capricor Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Capricor Therapeutics 2025-08-11
financial results
Read article

Atara Biotherapeutics Announces Second Quarter Financial Results and Operational Progress

Atara Biotherapeutics 2025-08-11
financial results
Read article

Protara Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update

protara therapeutics 2025-08-11
financial results
Presentation of interim analysis from approximately 25 six-month evaluable BCG-Unresponsive patients in the ongoing ADVANCED-2 trial expected at a medical conference in 1Q 2026 Dosing of first patient in THRIVE-3 registrational trial of IV Choline Chloride in patients dependent on parenteral
Read article

BrainStorm to Announce Second Quarter Financial Results and Provide a Corporate Update

BrainStorm Cell Therapeutics 2025-08-08
financial results
Read article

Lisata Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Lisata Therapeutics 2025-08-07
financial results
Cash runway extending into the fourth quarter of 2026 with no debt, funding current clinical programs through to their next data milestone Conference call scheduled for today at 4:30 p.m. Eastern Time BASKING RIDGE, N.J., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc.
Read article

IN8bio Reports Second Quarter 2025 Financial Results and Recent Business Highlights

In8Bio 2025-08-07
financial results
Delivered an oral presentation at ASCO 2025 Annual Meeting, demonstrating extended median progression-free survival (mPFS) in patients receiving multiple doses of INB-200, including a patient remaining progression-free for over four years. Received the Host Region USA East Abstract Award at ISCT
Read article

PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results

ptc biotherapeutics 2025-08-07
financial results
– European and FDA approval of Sephience™ (sepiapterin) with broad labeling for PKU – – Global launch underway in Europe and U.S. – – Total Q2 Revenue of $179M – WARREN, N.J. , Aug. 7, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. , (NASDAQ: PTCT) today announced a corporate update and financial
Read article

Cabaletta Bio Reports Second Quarter 2025 Financial Results and Provides Business Update

cabaletta bio 2025-08-07
financial results
Read article

Capricor Therapeutics to Present Second Quarter 2025 Financial Results and Recent Corporate Update on August 13

Capricor Therapeutics 2025-08-06
financial results
Read article

Ultragenyx Reports Second Quarter 2025 Financial Results and Corporate Update—Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical 2025-08-05
financial results
The Investor Relations website contains information about Ultragenyx Pharmaceutical Inc.'s business for stockholders, potential investors, and financial analysts.
Read article

Axogen, Inc. Reports Second Quarter 2025 Financial Results

axogen 2025-08-05
financial results
Read article

Cryoport Reports Second Quarter 2025 Financial Results

Cryoport Inc 2025-08-05
financial results
Read article

AbbVie Reports Second-Quarter 2025 Financial Results

Abbvie Investors 2025-07-31
financial results
Reports Second-Quarter Diluted EPS of $0.52 on a GAAP Basis, a Decrease of 32.5 Percent; Adjusted Diluted EPS of $2.97 , an Increase of 12.1 Percent; These Results Include an Unfavorable Impact of $0.42 Per Share Related to Acquired IPR&D and Milestones Expense Delivers Second-Quarter Net
Read article

REGENXBIO to Host Conference Call on August 7 to Discuss Second Quarter 2025 Financial Results and Operational Highlights

REGENXBIO 2025-07-31
financial results
ROCKVILLE, Md. , July 31, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Thursday, August 7 , at 8:00 a.m. ET to discuss its financial results for the second quarter ended June 30, 2025 , and operational highlights.
Read article

Ultragenyx to Host Conference Call for Second Quarter 2025 Financial Results and Corporate Update—Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical 2025-07-30
financial results
The Investor Relations website contains information about Ultragenyx Pharmaceutical Inc.'s business for stockholders, potential investors, and financial analysts.
Read article

LENZ Therapeutics Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

LENZ Therapeutics 2025-07-30
financial results
Read article

Roivant to Report Financial Results for the First Quarter Ended June 30, 2025, and Provide Business Update on Monday, August 11, 2025

roivant 2025-07-28
financial results
BASEL, Switzerland and LONDON and NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Monday, August 11, 2025, to report its financial results for the first quarter ended June 30, 2025, and
Read article

Axogen, Inc. to report 2025 second quarter financial results on August 5, 2025

axogen 2025-07-22
financial results
Read article

Cryoport to Report Second Quarter 2025 Financial Results on August 5, 2025

Cryoport Inc 2025-07-22
financial results
Read article

PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2025 Financial Results

ptc biotherapeutics 2025-07-21
financial results
WARREN, N.J. , July 21, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the company will host a webcast conference call to report its second quarter 2025 financial results and provide an update on the company's business and outlook on Thursday, August 7 , at 4:30
Read article

AbbVie to Host Second-Quarter 2025 Earnings Conference Call

Abbvie Investors 2025-06-30
financial results
NORTH CHICAGO, Ill. , June 30, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its second-quarter 2025 financial results on Thursday, July 31, 2025 , before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time .
Read article

Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025, and Provides Business Update

roivant 2025-05-29
financial results
BASEL, Switzerland and LONDON and NEW YORK, May 29, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today reported its financial results for the fourth quarter and fiscal year ended March 31, 2025, and provided a business update. Brepocitinib program progressing well with rapid enrollment in
Read article

Century Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Century Therapeutics 2025-05-15
financial results
Read article

Atara Biotherapeutics Announces First Quarter Financial Results and Operational Progress

Atara Biotherapeutics 2025-05-15
financial results
Read article

Nkarta Reports First Quarter 2025 Financial Results and Corporate Highlights

nkarta 2025-05-14
open lupus nkx019 financial results myasthenia gravis
Enrollment open in investigator-sponsored trial (IST) of NKX019 in myasthenia gravis; Ntrust-1, Ntrust-2, and IST of NKX019 in systemic lupus erythematosus remain open to enrollment Ntrust-1 expanded to include primary membranous nephropathy cohort Lymphodepletion regimen modified across platform
Read article

Kalaris Reports First Quarter 2025 Financial Results and Provides Business Highlights | Wed, 05/14/2025

Kalaris Therapeutics 2025-05-14
financial results
Actively enrolling nAMD patients in a Phase 1 trial of TH103, a novel, differentiated anti-VEGF agent engineered to potentially provide longer-lasting and increased anti-VEGF activity to treat neovascular and exudative diseases of the retina; initial clinical data is expected in Q4 2025 Cash and
Read article

Benitec Biopharma Releases Third Quarter 2025 Financial Results

benitec biopharma 2025-05-14
financial results
Read article

Passage Bio Reports First Quarter 2025 Financial Results and Provides Recent Business Highlights

passage bio 2025-05-13
financial results
Read article

Adaptimmune Reports Q1 Financial Results and Provides Business Update

Adaptimmune Therapeutics 2025-05-13
bla open pivotal sarcoma tecelra solid tumor cell therapy cell therapies synovial sarcoma financial results
TECELRA ® launch 2025 YTD metrics: 28 ATCs available; 21 patients aphresed; and 14 doses invoiced $4.0 million Tecelra net sales in Q1 2025 Instituting 2025 Tecelra full year sales guidance of $35-$45 million Lete-cel on track to initiate rolling BLA submission late 2025; approval anticipated in 2026 Adaptimmune had Total Liquidity 1 of $60 million as of March 31, 2025; call at 8 a.m. EDT today Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - May 13, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, today reported financial results and provided a business update for the first quarter ended March 31, 2025. Adrian Rawcliffe, Adaptimmune's Chief Executive Officer: "The launch of Tecelra continues to rapidly accelerate, as evidenced by all launch metrics. In Q4 2024 we invoiced 2 patients, in Q1 2025 we invoiced 6 patients, and in Q2 to-date we have invoiced 8 patients. The shape of the pipeline of patients being tested and apheresed continues to support a robust acceleration of sales in Q2 and the second half of the year, and we continue to experience 100% manufacturing success…
Read article

Kyverna Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results

Kyverna Therapeutics 2025-05-13
bla kyv-101 financial results myasthenia gravis stiff person syndrome
Enrollment complete in registrational Phase 2 KYV-101 trial in stiff person syndrome (SPS); on track for topline data in 1H 2026; biologics license application (BLA) filing now anticipated in 1H 2026 Advancing into registrational Phase 3 KYV-101 trial in myasthenia gravis (MG) following successful
Read article

Cellectis Reports Financial Results for the First Quarter 2025

cellectis 2025-05-12
b-all car t leukemia allogeneic base editing gene editing gene therapy gene therapies hodgkin lymphoma financial results in vivo gene therapy non-hodgkin lymphoma hematological malignancies acute lymphoblastic leukemia b-cell acute lymphoblastic leukemia
Lasme-cel (UCART22) Phase 1 dataset and late-stage development strategy expected in the third quarter of 2025 Eti-cel (UCART20x22) Phase 1 study in relapsed or refractory B-cell non-Hodgkin lymphoma (r/r NHL) ongoing with readout expected in late 2025 AstraZeneca partnership: R&D activities ongoing on three programs – one allogeneic CAR T for hematological malignancies, one allogeneic CAR T for solid tumors, and one in vivo gene therapy for a genetic disorder Cellectis will present novel non-viral gene editing and base editing research at the 2025 ASGCT annual meeting Cash position of $246 million as of March 31, 2025 [1] provides runway into H2 2027 New York, NY – May 12, 2025 - Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today provided financial results for the first quarter 2025, ending March 31, 2025, and provided a business update. « We are making progress in our wholly-owned clinical studies and in the three programs under our strategic partnership with AstraZeneca. We will continue to focus our efforts and resources on…
Read article

Celularity Announces Full Year 2024 Operating and Financial Results

celularity 2025-05-09
financial results
Read article

Turnstone Biologics Corp. Reports First Quarter 2025 Financial Results and Provides Recent Corporate Highlights

Turnstone Bio 2025-05-08
financial results
SAN DIEGO, May 08, 2025 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq-CM: TSBX) , a biotechnology company historically focused on the development of a differentiated approach to treat and cure patients with solid tumors by pioneering selected
Read article

ProQR Announces First Quarter 2025 Operating and Financial Results

proqr therapeutics 2025-05-08
financial results
Axiomer™ ADAR-mediated RNA editing pipeline advancing across liver and CNS programs, with CTA filing on track for Q2 2025 for lead program AX-0810 targeting NTCP for Cholestatic diseases  Strengthened leadership with appointments of Chief Financial Officer and Chief Medical Officer € 132.4 million cash and cash equivalents as of end Q1 providing runway into mid-2027, plus additional potential milestones from Lilly partnership LEIDEN, Netherlands & CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer RNA editing technology platform, today reported its financial and operating results for the first quarter ended March 31, 2025, and provided a business update.
Read article

Caribou Biosciences Reports First Quarter 2025 Financial Results and Provides Business Update

caribou biosciences 2025-05-08
financial results
Two robust clinical datasets from CB-010 and CB-011 expected to be disclosed in H2 2025 -- -- $212.5 million in cash, cash equivalents, and marketable securities expected to fund the Company’s current operating plan into H2 2027 -- BERKELEY, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Caribou
Read article

Axogen, Inc. Reports 2025 First Quarter Financial Results

axogen 2025-05-08
financial results
Read article

IN8bio Reports First Quarter 2025 Financial Results and Recent Business Highlights

In8Bio 2025-05-07
aml leukemia financial results acute myeloid leukemia
Phase 1 clinical data of INB-100 continues to demonstrate long-term durable remissions, with 100% of treated Acute Myeloid Leukemia (AML) patients remaining relapse-free with median follow-up of 20.1 months as of January 17, 2025, as presented at the 2025 Transplantation & Cellular Therapy (TCT)
Read article

Cryoport Reports First Quarter 2025 Financial Results

Cryoport Inc 2025-05-07
financial results
Read article

Adicet Bio Reports First Quarter 2025 Financial Results and Provides Business Updates

Adicet Bio 2025-05-07
open lupus financial results
Two programs with clinical data readouts in 2H/2025 Phase 1 clinical trial of ADI-001 in autoimmune diseases ongoing with preliminary clinical data expected in 2H/2025; Trial now open for enrollment to patients with lupus nephritis (LN) and systemic lupus erythematosus (SLE) Preliminary data for
Read article

Adaptimmune to Report Q1 2025 Financial and Business Updates on Tuesday, May 13, 2025

Adaptimmune Therapeutics 2025-05-07
open quarterly solid tumor cell therapy cell therapies financial results
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - May 7, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, will report financial results and provide business updates for the first quarter of 2025, before the US markets open on Tuesday, May 13, 2025. Following the announcement, the Company will host a live webcast at 8:00 a.m. EDT that same day. The press release will be available in the investor section of Adaptimmune's corporate website . A live webcast and replay can be accessed at https://www.gowebcasting.com/14032 . Call in information is as follows: 1-833-821-0158 (US or Canada) or 1-647-846-2266 (International). Callers should dial in 5-10 minutes prior to the scheduled start time and simply ask to join the Adaptimmune call. About Adaptimmune Adaptimmune is a clinical-stage biopharmaceutical company focused on designing, developing, and delivering cell therapies to transform the lives of people with cancer. The Company's unique engineered T-cell receptor (TCR) platform enables the engineering of T-cells to target and destroy cancers across multiple solid tumor types.…
Read article

Cellectis to Report First Quarter Financial Results on May 12, 2025

cellectis 2025-05-06
gene therapies financial results
New York, NY – May 6, 2025 - Cellectis (the “Company”) (Euronext Growth: ALCLS- NASD AQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the first quarter 2025 ending March 31, 2025 on Monday, May 12, 2025 after the close of the US market. The press release will be available in the Investors section of Cellectis’ website: https://www.cellectis.com/en/investors/press-releases/ Cellectis will not host a conference call to discuss these results. Our investors relations team remains available for questions at investors@cellectis.com
Read article

AbbVie Reports First-Quarter 2025 Financial Results

Abbvie Investors 2025-04-25
financial results
Reports First-Quarter Diluted EPS of $0.72 on a GAAP Basis, a Decrease of 6.5 Percent; Adjusted Diluted EPS of $2.46 , an Increase of 6.5 Percent; These Results Include an Unfavorable Impact of $0.13 Per Share Related to Acquired IPR&D and Milestones Expense Delivers First-Quarter Net Revenues
Read article

Axogen, Inc. to report 2025 first quarter financial results on May 8, 2025

axogen 2025-04-24
financial results
Read article

AbbVie to Host First-Quarter 2025 Earnings Conference Call

Abbvie Investors 2025-03-31
financial results
NORTH CHICAGO, Ill. , March 31, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its first-quarter 2025 financial results on Friday, April 25, 2025 , before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time .
Read article

Turnstone Biologics Corp. Reports Fourth Quarter and Full Year 2024 Financial Results

Turnstone Bio 2025-03-29
financial results
SAN DIEGO, March 28, 2025 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a biotechnology company historically focused on the development of a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating
Read article

Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Kyverna Therapeutics 2025-03-27
lupus financial results myasthenia gravis stiff person syndrome
Accelerating clinical path to commercialization in stiff person syndrome, myasthenia gravis and lupus nephritis Aligned with the U.S. Food and Drug Administration (FDA) on a registrational Phase 2 trial design for ongoing KYSA-8 trial in stiff person syndrome; 70% of study enrolled with topline
Read article

Nkarta Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights

nkarta 2025-03-26
nkx019 financial results
Differentiated development program includes two Nkarta clinical trials and two investigator-sponsored trials of NKX019 in rheumatic and neurological diseases Initial data for NKX019 in multiple autoimmune indications expected in second half of 2025 Restructuring and workforce reduction of 34% (53
Read article

MiNK Therapeutics Reports Fourth Quarter & Full Year 2024 Results and Highlights Business Progress

Mink Therapeutics 2025-03-19
allogeneic cell therapies financial results
NEW YORK , March 18, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies, today announced its financial results for the fourth quarter and
Read article

Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results

Sangamo BioSciences 2025-03-18
financial results
The Investor Relations website contains information about Sangamo Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts.
Read article

Tourmaline Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Talaris Therapeutics 2025-03-13
financial results
– Phase 2 TRANQUILITY trial in patients with elevated high-sensitivity C-reactive protein and chronic kidney disease over-enrolled to 143 total participants, on track to report topline data in the second quarter of 2025 – – Cardiovascular Scientific Advisory Board strengthened with recent
Read article

Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2024 and Provides a Business Update

cellectis 2025-03-13
car t allogeneic orphan drug gene editing gene therapy gene therapies hodgkin lymphoma financial results in vivo gene therapy non-hodgkin lymphoma hematological malignancies
UCART22 Phase 1 dataset and late-stage development strategy expected in the third quarter of 2025; Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPDD) granted by FDA and ODD granted by the European Commission to UCART22 for the treatment of ALL. UCART20x22 Phase 1 study in relapsed or refractory B-cell non-Hodgkin lymphoma (r/r NHL) ongoing with readout expected in late 2025. AstraZeneca partnership: R&D activities ongoing on three programs – one allogeneic CAR T for hematological malignancies, one allogeneic CAR T for solid tumors, and one in vivo gene therapy for a genetic disorder . Cash position of $264 million as of December 31, 2024 [1] provides runway into mid-2027. Conference call March 14, 2025 at 8:00 am ET / 1:00 pm CET . [1] Cash position includes cash, cash equivalents, restricted cash and fixed-term deposits classified as current -financial assets. Restricted cash was $4.6 million as of December 31, 2024. Fixed-term deposits classified as current-financial assets was $115.8 million as of December 31, 2024. New York, NY – March 13, 2025 - Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company…
Read article

Adaptimmune to Report Full Year and Q4 2024 Financial and Business Updates on Thursday, March 20, 2025

Adaptimmune Therapeutics 2025-03-12
open quarterly solid tumor cell therapy cell therapies financial results
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - March 12, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, will report financial results and provide business updates for the fourth quarter and full year ended December 31, 2024, before the US markets open on Thursday, March 20, 2025. Following the announcement, the Company will host a live webcast at 8:00 a.m. EDT that same day. The press release will be available in the investor section of Adaptimmune's corporate website . A live webcast and replay can be accessed at https://www.gowebcasting.com/13966 . Call in information is as follows: 1-833-821-0158 (US or Canada) or 1-647-846-2266 (International). Callers should dial in 5-10 minutes prior to the scheduled start time and simply ask to join the Adaptimmune call. About Adaptimmune Adaptimmune is a clinical-stage biopharmaceutical company focused on designing, developing, and delivering cell therapies to transform the lives of people with cancer. The Company's unique engineered T-cell receptor (TCR) platform enables the engineering of T-cells to target and destroy cancers…
Read article

Cellectis to Report Fourth Quarter and Full Year 2024 Financial Results on March 13, 2025

cellectis 2025-03-07
gene therapies financial results
New York, NY – March 7, 2025 - Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the fourth quarter and full year 2024 ending December 31, 2024 on Thursday, March 13, 2025 after the close of the US market. The publication will be followed by an investor conference call and webcast on Friday, March 14, 2025, at 8:00 AM ET / 1:00 PM CET. The call will include the Company’s fourth quarter and full year 2024 results and an update on business activities. Details for the call are as follows: Dial in information: Domestic: +1-800-225-9448 International: +1-203-518-9708 Conference ID: CLLS24 Webcast Link: https://viavid.webcasts.com/starthere.jsp?ei=1706599&tp_key=4524940f8f
Read article

Atara Biotherapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Operational Progress

Atara Biotherapeutics 2025-03-07
financial results
Read article

Adicet Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Company Progress

Adicet Bio 2025-03-07
lupus financial results
Phase 1 clinical trial of ADI-001 in autoimmune diseases ongoing; on track to report preliminary clinical data from lupus nephritis (LN) patient cohort in 1H25 Additional LN clinical data and preliminary clinical data from other autoimmune patient cohorts anticipated in 2H25 Initiation of ADI-001
Read article

Passage Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Recent Business Highlights

passage bio 2025-03-04
financial results
Read article

Axogen, Inc. Reports 2024 Fourth Quarter and Full-Year Financial Results

axogen 2025-02-25
financial results
Read article

Axogen, Inc. to report 2024 fourth quarter and full year financial results on February 25, 2025

axogen 2025-02-11
financial results
Read article

Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2024 Financial Results

Sangamo BioSciences 2024-11-12
financial results
The Investor Relations website contains information about Sangamo Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts.
Read article

Axogen, Inc Reports Third Quarter 2024 Financial Results and Provides BLA Update

axogen 2024-11-07
bla financial results
Read article

Carisma Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

carisma therapeutics 2024-11-07
gpc3 financial results
Initial results from the Phase 1 study of CT-0525, lead product candidate, expected in the first quarter of 2025 Nomination of a development candidate for liver fibrosis program expected in the first quarter of 2025 New preclinical efficacy data from the anti-GPC3 in vivo CAR-M therapy to be
Read article

Cellectis Provides Business Updates and Financial Results for Third Quarter 2024

cellectis 2024-11-04
car t pivotal allogeneic cell therapy gene editing gene therapy gene therapies financial results in vivo gene therapy hematological malignancies
UCART22 and UCART20x22: enrollment ongoing, Phase 1 dataset and late-stage development strategy to be presented in 2025 AstraZeneca partnership: R&D activities are ongoing on three programs – one allogeneic CAR T for hematological malignancies, one allogeneic CAR T for solid tumors, and one in vivo gene therapy for a genetic disorder Appointed Adrian Kilcoyne, M.D., MPH, MBA, an industry leader in the advancement of cell therapy treatment, as Chief Medical Officer Cash position of $2 64 million as of September 30, 2024 [1] ; cash runway projection into 2027 Conference call scheduled for 8:00 am ET / 2:00 pm CET on November 5, 2024 New York, NY – November 4, 2024 - Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today provided business updates and reported financial results for the nine-month period ending September 30, 2024. “This quarter, we were thrilled to welcome Dr. Kilcoyne to Cellectis as Chief Medical Officer. Dr. Kilcoyne joins us at a pivotal time for the Company, bringing extensive experience in drug development as we are…
Read article

Cellectis to Report Third Quarter 2024 Financial Results on November 4, 2024

cellectis 2024-10-30
gene therapies financial results
New York, NY – October 30, 2024 - Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the third quarter 2024 ending September 30, 2024 on Monday, November 4, 2024 after the close of the US market. The publication will be followed by an investor conference call and webcast on Tuesday, November 5, 2024 at 8:00 AM ET / 2:00 PM CET. The call will include the Company’s third quarter results and an update on business activities. Details for the call are as follows: Dial in information: Domestic: +1-800-225-9448 International: +1-203-518-9708 Conference ID: CLLSQ3 Webcast Link: https://viavid.webcasts.com/starthere.jsp?ei=1688144&tp_key=affca25222
Read article

Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2024 Financial Results

Sangamo BioSciences 2024-08-06
financial results
The Investor Relations website contains information about Sangamo Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts.
Read article

Cellectis Provides Financial Results for the Second Quarter 2024

cellectis 2024-08-06
bla leukemia orphan drug gene editing gene therapies priority review financial results acute lymphoblastic leukemia
ODD and RPDD granted by the FDA and ODD granted by the European Commission to UCART22 for the treatment of ALL ODD granted by the FDA to CLLS52 (alemtuzumab) for ALL treatment Cash position of $273 million as of June 30, 2024 [1] ; cash runway projection into 2026 New York, NY – August 6, 2024 - Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today provided business updates and reported financial results for the six-month period ending June 30, 2024. "Over the past months, we have achieved a significant milestone with the granting of ODD designations by the Food and Drug Administration and the European Commission, complemented by the FDA’S Rare Pediatric Disease Designation. We have overcome major challenges, which reflects our ongoing commitment to innovation. Driven by an unwavering belief in our ability to revolutionize the healthcare field, we continue our pursuit of advancement with the confidence that our work will lead to the launch of a life-saving drug product. Our determination is the engine of our future success” said André…
Read article

Cellectis Reports Financial Results for First Quarter 2024

cellectis 2024-05-28
gene editing gene therapy gene therapies financial results
Cellectis announced completion of the additional equity investment of $140M by AstraZeneca Cash position of $143 million as of March 31, 2024 [1] ; cash runway projection into 2026 [2] Conference call and webcast scheduled for tomorrow, May 29, 2024 at 8:00AM ET / 2:00PM CET New York, NY – May 28, 2024 - Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today provided business updates and reported financial results for the three-month period ending March 31, 2024. “We are thrilled to have announced the closing of the additional equity investment of $140 million by AstraZeneca. This followed AstraZeneca’s initial payment of $105 million, composed of a $80 million equity investment and a $25 million upfront payment under our research collaboration. Following AstraZeneca’s additional investment, we expect our cash runway to fund operations into 2026. We will continue to focus our efforts and expenses on advancing its core clinical trials BALLI-01, NATHALI-01 and AMELI-01, which remain wholly owned assets, while building, within our owned…
Read article

Cellectis to Report First Quarter 2024 Financial Results on May 28, 2024

cellectis 2024-05-25
gene therapies financial results
New York, NY – May 27, 2024 - Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the first quarter 2024 ending March 31, 2024 on Tuesday, May 28, 2024 after the close of the US market. The publication will be followed by an investor conference call and webcast on Wednesday, May 29, 2024 at 8:00 AM ET / 2:00 PM CET. The call will include the Company’s first quarter results and an update on business activities. Details for the call are as follows: Dial in information: Domestic: 1-877-451-6152 International: 1-201-389-0879 Conference ID: 13746795 Webcast Link: https://viavid.webcasts.com/starthere.jsp?ei=1672725&tp_key=f83e7ab481
Read article

Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2023

cellectis 2024-04-29
cd19 car t autologous gene editing cell therapies gene therapies financial results
Preliminary results of NATHALI-01 and updated results of BALLI-01 Phase I clinical studies presented at the American Society of Hematology (ASH) 65th Annual Meeting Execution of strategic collaboration and investment agreements with AstraZeneca Cécile Chartier, Ph.D., appointed as a director of the Cellectis’ Board of Directors Drawdown of the second tranche of €15 million under the credit facility agreement entered into with the European Investment Bank (EIB) Cash position of $156 million as of December 31, 2023 [1] [1] Cash position includes cash, cash equivalents, restricted cash and fixed-term deposits classified as current -financial assets . Restricted cash was $5 million as of December 31, 2023. Fixed-term deposits classified as current-financial assets was $15 million as of December 31, 2023. New York, NY – April 29, 2024 - Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today provided business updates and reports preliminary financial results for the fourth quarter and full year 2023, ending December 31, 2023. “Cellectis…
Read article

Athersys Reports Third Quarter 2023 Financial Results and Business Highlights

athersys 2023-11-16
financial results
Read article

Alaunos Therapeutics Announces Third Quarter 2023 Financial Results, Phase 1 Clinical Data and Continued Exploration of Strategic Alternatives

Alaunos 2023-11-14
tcr-t phase 1/2 cell therapy financial results
TCR-T Library Phase 1/2 trial achieved an 87% disease control rate of eight evaluable patients with metastatic, refractory solid tumors; TCR-T cell therapy was well tolerated in all treated patients hunTR® discovered new HLA class I and class II restricted TCRs that recognize driver mutations,
Read article

Cellectis Reports Financial Results for Third Quarter and First Nine Months 2023

cellectis 2023-11-06
aml car t allogeneic gene editing gene therapy gene therapies financial results
Strategic Collaboration and Investment Agreements signed with AstraZeneca Updated results of the Phase I BALLI-01 Trial evaluating UCART22 in r/r B-cell ALL and preliminary results of the Phase I NATHALI-01 Trial evaluating UCART20x22 in r/r B-cell NHL to be presented at ASH 65 th Annual meeting. Clinical trials ongoing: BALLI-01 (evaluating UCART22), NATHALI-01 (evaluating UCART20x22) and AMELI-01 (evaluating UCART123) studies for patients with r/r B-cell ALL, r/r B-cell NHL and r/r AML, respectively. Preclinical data on HSPC gene therapy and a comprehensive analysis of TALE-BE editing determinants presented at ESGCT 2023 30 th annual congress. Preclinical data on Multi-armored Allogeneic MUC1-CAR T-cells targeting Triple-Negative Breast at SITC 2023 annual event. Cash position of $72 [1] million as of September 30, 2023. Cash runway into 2026 including Initial AstraZeneca Investment and Potential Additional AstraZeneca Investment. Conference call scheduled for 8.00am ET / 2.00 pm CET on November 7, 2023 New York, NY – November 6, 2023 - Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing…
Read article

Cellectis to Report Third Quarter 2023 Financial Results on November 6, 2023

cellectis 2023-11-01
gene therapies financial results
New York, NY – November 1, 2023 - Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the third quarter ended September 30, 2023 on Monday, November 6, 2023 after the close of the US market. The announcement will be followed by an investor conference call and webcast on Tuesday, November 7, 2023 at 8:00 AM ET / 2:00 PM CET. The call will include the Company’s third quarter results and an update on business activities. Details for the call are as follows: Dial in information: Domestic: 1-877-451-6152 International: 1-201-389-0879 Conference ID: 13741035 Webcast Link: https://viavid.webcasts.com/starthere.jsp?ei=1632799&tp_key=bff99741ab
Read article

Athersys Reports Second Quarter 2023 Financial Results and Business Highlights

athersys 2023-08-16
financial results
Read article

Alaunos Therapeutics Announces Second Quarter 2023 Financial Results, Interim Clinical Data and Exploration of Strategic Alternatives

Alaunos 2023-08-14
tcr-t phase 1/2 cell therapy financial results
TCR-T Library Phase 1/2 trial achieved an 83% disease control rate of six evaluable patients with metastatic, refractory solid tumors; TCR-T cell therapy was well tolerated in all evaluable patients Company to wind down TCR-T Library Phase 1/2 trial and concurrently explore potential partnering
Read article

Cellectis Provides Full Report for Second Quarter 2023 Financial Results

cellectis 2023-08-07
gene therapies financial results financial statements
New York, NY – August 7, 2023 - Cellectis S.A. (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the release of the full report of the financial results for the second quarter 2023 (ended June 30, 2023) and filing of the corresponding 6-K with the SEC. Financial Results The interim condensed consolidated financial statements of Cellectis, have been prepared in accordance with International Financial Reporting Standards, as issued by the International Accounting Standards Board (“IFRS”). We present certain financial metrics broken out between our two reportable segments – Therapeutics and Plants – in the appendices of this Q2 2023 financial results press release. On January 13, 2023, Calyxt, Cibus Global LLC (Cibus) and certain other parties named therein, entered into an Agreement and Plan of Merger (the “Merger Agreement”), pursuant to which, subject to the terms and conditions thereof, Calyxt and Cibus will merge in an all-stock transaction (the “Calyxt Merger”). As a consequence of the foregoing, Calyxt met the “held-for-sale”…
Read article

Cellectis Provides Business Updates and Preliminary Financial Results for Second Quarter 2023

cellectis 2023-08-03
aml cd19 b-all car t allogeneic cell therapy gene therapies financial results financial statements
Updated clinical & translational data on BALLI-01 trial (evaluating UCART22 in r/r B-cell ALL) presented at the EHA annual meeting * Clinical trials ongoing: BALLI-01 (evaluating UCART22), NATHALI-01 (evaluating UCART20x22) and AMELI-01 (evaluating UCART123) studies for patients with r/r B-cell ALL, r/r B-cell NHL and r/r AML, respectively * Preclinical data presented on HBB gene correction of sickle cell mutation & TALE Base Editors (TALE-BE) at ISCT 2023 annual event * Appointment of Cécile Chartier, Ph.D., as Director to Cellectis’ Board of Directors * Cash position [1] of $89 million as of June 30, 2023. Cash runway into Q3 2024 * Full financial statements for the second quarter of 2023 will be released in the coming days * Conference call scheduled for 8AM ET/2PM CET on August 4, 2023 New York, NY – August 3, 2023 - Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today provided business updates and preliminary financial results for the six-month period ending June 30, 2023. Full report of the financial results for the second…
Read article

Cellectis to Report Second Quarter 2023 Financial Results on August 3, 2023

cellectis 2023-07-26
gene therapies financial results
New York, NY – July 27, 2023 - Cellectis S.A. (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the second quarter ended June 30, 2023 on Thursday, August 3, 2023 after the close of the US market. The announcement will be followed by an investor conference call and webcast on Friday, August 4, 2023 at 8:00 am ET / 2:00 pm CET. The call will include the Company’s second quarter results and an update on business activities. Details for the call are as follows: Dial in information: Domestic: 1-877-451-6152 International: 1-201-389-0879 Conference ID: 13739252 Webcast Link: https://viavid.webcasts.com/starthere.jsp?ei=1619596&tp_key=40e9fac8fc
Read article

Alaunos Therapeutics Reports First Quarter 2023 Financial Results

Alaunos 2023-05-10
tcr-t precigen phase 1/2 precigen inc. financial results
Actively enrolling patients and manufacturing cryopreserved products for TCR-T Library Phase 1/2 trial; expect to report interim data in the third quarter of 2023 Fully prepaid loan with Silicon Valley Bank; now a debt-free company Amended exclusive licensing agreement with Precigen, Inc.,
Read article

Cellectis Provides Business Update and Reports Financial Results for First Quarter 2023

cellectis 2023-05-04
car t talen leukemia allogeneic gene therapies financial results acute lymphoblastic leukemia b-cell acute lymphoblastic leukemia
First r/r ALL patient dosed in Europe with Cellectis’ UCART22 product candidate manufactured in-house Cellectis implements CLLS52 for the first time in the clinic with Sanofi’s alemtuzumab Cellectis stops enrollment and treatment of patients in the MELANI-01 clinical trial evaluating UCARTCS1 product candidate in r/r MM Encouraging preclinical data on TALEN ® -edited MUC1 CAR T-cells presented at the AACR 2023 annual meeting Two abstracts accepted for oral and poster presentations at the upcoming ASGCT annual meeting Cash position [1] of 88$ million as of March 31, 2023 Conference call scheduled for 8AM ET/2PM CET on May 5, 2023 New York, NY – May 4, 2023 - Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today provided a business update and announced its results for the three-month period ending March 31, 2023. “ Cellectis took a notable step forward this quarter with the first patient being dosed in France with our in-house manufactured product candidate UCART22 in the BALLI-01 clinical study. UCART22 is currently the most advanced…
Read article

Cellectis to Report First Quarter 2023 Financial Results on May 4, 2023

cellectis 2023-04-27
gene therapies financial results
New York, NY — April 27, 2023 — Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies , today announced that it will report financial results for the first quarter ended March 31, 2023, on Thursday, May 4, 2023 after the close of the US market. The announcement will be followed by an investor conference call and webcast on Friday, May 5, 2023 at 8:00 am ET / 2:00 pm CET. The call will include the Company’s first quarter results and an update on business activities. Details for the call are as follows: Dial-in Information: Domestic: 1-877-451-6152 International: 1-201-389-0879 Conference ID: 13737755 Webcast Link: https://viavid.webcasts.com/starthere.jsp?ei=1608110&tp_key=92e9a57eb8
Read article

Cellectis Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results

cellectis 2023-03-08
aml gene therapies financial results
Entered into a € 40 million credit facility with the European Investment Bank and closed an approximatively $25 million follow-on equity offering to support Cellectis’ research, development and innovation activities Positive preliminary clinical data from Phase 1 BALLI-01 study (evaluating UCART22) for patients with r/r B-cell ALL presented in a Live Webcast; First patient dosed with UCART22 product candidate fully manufactured in-house Encouraging preliminary results from Phase 1 AMELI-01 study (evaluating UCART123) for patients with AML presented at an oral session at ASH 2022; AMELI-01 currently enrolling in a two-dose regimen arm at DL2 Partner Allogene Therapeutics initiated Phase 2 of ALPHA2 trial in relapsed/refractory Large B Cell Lymphoma (r/r LBCL) Cellectis partnered with Primera Therapeutics to edit mutations in the mitochondrial DNA (mtDNA) in vivo Cash position of $95 million as of December 31, 2022 [1] Conference call scheduled for 8AM ET/2PM CET on March 9, 2023 New York (N.Y) - March 8, 2023 – Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving…
Read article

Calyxt, Inc. Reports its Fourth Quarter 2022 Financial Results and Provides Corporate Update

cellectis 2023-03-06
gene editing gene therapies financial results
New York, NY – March 6, 2023 – Cellectis S.A. (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biology company for which Cellectis owns 49.1% (as of December 31, 2022) of its issued and outstanding common stock, today announced operating and financial results for its fourth quarter ended December 31, 2022. The contents of Calyxt’s announcement are included below: Announced proposed merger with Cibus Global and filed initial registration statement on Form S-4 — —Current customer projects under development are on track— —Signed agreement with Evologic Technologies to further develop and scale production of its Plant Cell Matrix™ and BioFactory TM technologies— Merger Agreement with Cibus On January 17, 2023, Calyxt announced it had entered into a definitive merger agreement with Cibus Global, LLC (Cibus), a leader in precision gene editing in agriculture, under which Calyxt and Cibus will merge in an all-stock transaction. The merger will create a new industry-leading company that combines…
Read article

Cellectis to Report Fourth Quarter and Year-End 2022 Financial Results on March 8, 2023

cellectis 2023-03-01
gene therapies financial results
March 1 st , 2023 - New York, NY - Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the fourth quarter and year-end 2022 ending December 31 st , 2022, on Wednesday, March 8, 2023, after the close of the US market. The announcement will be followed by a conference call and live audio webcast on Thursday, March 9, 2023, at 8:00 AM ET / 2:00 PM CET. The call will include the Company’s fourth quarter results, year-end results, and an update on business activities. Details for the call are as follows: Dial-in information: Domestic: 1-877-451-6152 International : 1-201-389-0879 Call Me Link: https://callme.viavid.com/viavid/?callme=true&passcode=13727032&h=true&info=company-email&r=true&B=6 Webcast Link: https://viavid.webcasts.com/starthere.jsp?ei=1598389&tp_key=25a6baeb0f
Read article

Cellectis Provides Business Update and Reports Financial Results for Third Quarter and First Nine Months 2022

cellectis 2022-11-03
gm1 til car t talen pivotal leukemia melanoma allogeneic cell therapy gene therapy gene therapies b-cell lymphoma financial results large b-cell lymphoma acute myeloid leukemia
ASH 2022 sponsored programs – UCART123 abstract selected for oral presentation & preclinical data on UCARTCS1 selected for poster presentation, in collaboration with the Amsterdam University Medical Center -Preclinical data on TALEN®-edited smart CAR T-cells to be presented at SITC 2022 -Partner Allogene Therapeutics announced having initiated industry’s first allogeneic CAR T Phase 2 trial -Iovance Biotherapeutics, Inc. announced having dosed the first patient and completed safety observation period in its IOV-GM1-201 clinical trial -Mark Frattini, M.D., Ph.D., appointed Chief Medical Officer -Cash position[1] of $103 million as of September 30, 2022 -Conference call scheduled for 8AM ET/1PM CET on November 4, 2022 [1] Cash position includes cash, cash equivalent, current financial assets and restricted cash. Restricted cash was $5million as of September 30, 2022. November 3, 2022 - New York (N.Y.) - Cellectis (Euronext Growth: ALCLS – Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop potentially life-saving cell and gene therapies, announced its results for the three-month and nine-month periods ending September 30, 2022.…
Read article

Cellectis to Report Third Quarter 2022 Financial Results

cellectis 2022-10-27
gene therapies financial results
October 27, 2022 - New York, NY –– Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the third quarter ended September 30th, 2022, on Thursday, November 3rd, 2022, after the close of the US market. The announcement will be followed by a conference call and live audio webcast on Friday, November 4th, 2022, at 8:00 AM EDT / 2:00 PM CET. The call will include the Company’s third quarter results and an update on business activities. Details for the call are as follows: Friday, November 4th at 8:00 a.m. Eastern Time: Domestic: 1-877-413-2411 International :1-201-389-0882 Conference ID :13732988 Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1571941&tp_key=ebcf814947
Read article

Cellectis Provides Business Update and Reports Financial Results for Second Quarter 2022

cellectis 2022-08-04
aml ind cd19 cd20 cd22 b-all car t cd123 leukemia allogeneic cell therapy gene therapy gene therapies hodgkin lymphoma multiple myeloma financial results non-hodgkin lymphoma acute myeloid leukemia acute lymphoblastic leukemia b-cell acute lymphoblastic leukemia
IND clearance received from FDA for UCART20x22 for the treatment of Non-Hodgkin Lymphoma -Cellectis unveiled novel immune-evasive universal allogeneic CAR T-cell in Nature Communications; awarded oral presentation at ASGCT in May -Mr. Axel-Sven Malkomes & Dr. Donald A Bergstrom, M.D., Ph.D. appointed as Directors of Cellectis’ Board of Directors -Cash position [1] of $135 million as of June 30, 2022 -Conference call scheduled for 8AM ET/2PM CET on August 5, 2022 [1] Cash position includes cash, cash equivalents and current financial assets and restricted cash. Restricted cash was $5 million as of June 30, 2022. New York, NY – August 4, 2022 – Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today provided business update and announced its results for the six-month period ending June 30, 2022. “This is a very exciting time at Cellectis: earlier this week, we were proud to announce the FDA clearance of our Investigational New Drug application for UCART20x22, our product candidate being developed for patients with relapsed and refractory…
Read article

Cellectis to Report Second Quarter 2022 Financial Results

cellectis 2022-07-28
gene therapies financial results
July 28, 2022 - New York, NY –– Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the second quarter ended June 30th, 2022, on Thursday, August 4th, 2022, after the close of the US market. The announcement will be followed by a conference call and webcast on Friday, August 5th, 2022, at 8:00 AM EDT / 2:00 PM CET. The call will include the Company’s second quarter results and an update on business activities. Details for the call are as follows: Friday, August 5th at 8:00 am Eastern Time: Domestic: 1-877-451-6152 International:1-201-389-0879 Conference ID: 13731385 Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1558912&tp_key=9b34665e01
Read article

Kyverna Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results, Read More

Kyverna Therapeutics 1970-01-01
financial results
Read article

Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results, Read More

Kyverna Therapeutics 1970-01-01
financial results
Read article

REGENXBIO Reports Third Quarter 2025 Financial Results and Operational Highlights

REGENXBIO 1970-01-01
financial results
Read article

Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results, Read More

Kyverna Therapeutics 1970-01-01
financial results
Read article

REGENXBIO to Host Conference Call on November 6 to Discuss Third Quarter 2025 Financial Results and Operational Highlights

REGENXBIO 1970-01-01
financial results
ROCKVILLE, Md. , Oct. 29, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Thursday, November 6 , at 8:00 a.m. ET to discuss its financial results for the third quarter ended September 30, 2025 , and operational highlights.
Read article

REGENXBIO to Host Conference Call on November 6 to Discuss Third Quarter 2025 Financial Results and Operational Highlights

REGENXBIO 1970-01-01
financial results
Read article

Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results, Read More

Kyverna Therapeutics 1970-01-01
financial results
Read article

Kyverna Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results, Read More

Kyverna Therapeutics 1970-01-01
financial results
Read article

REGENXBIO Reports Third Quarter 2025 Financial Results and Operational Highlights

REGENXBIO 1970-01-01
bla pivotal financial results duchenne muscular dystrophy
RGX-202 program for Duchenne muscular dystrophy advancing rapidly, topline results expected early Q2 2026 and BLA submission mid-2026 Pivotal trial enrollment completed in October; confirmatory trial open and enrolling New 12-month analysis shows all participants demonstrate improved functional
Read article